

Review

Not peer-reviewed version

Diffuse Noxious Inhibitory Controls in Chronic Pain States: Insights from Pre-Clinical Studies

[Raquel Pereira-Silva](#), [Fani L. Neto](#)^{*}, [Isabel Martins](#)^{*}

Posted Date: 13 November 2024

doi: 10.20944/preprints202411.0922.v1

Keywords: Conditioned pain modulation; Descending pain modulation; Noradrenaline; Serotonin; Opioids; Brainstem; Chronic pain



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Review

Diffuse Noxious Inhibitory Controls in Chronic Pain States: Insights from Pre-Clinical Studies

Raquel Pereira-Silva ^{1,2,3}, Fani L. Neto ^{1,2,3,*} and Isabel Martins ^{1,2,3,*}

¹ Instituto de Investigação e Inovação em Saúde da Universidade do Porto – i3S; R. Alfredo Allen 208, 4200-135 Porto, Portugal

² Instituto de Biologia Molecular e Celular (IMBC), Universidade do Porto; R. Alfredo Allen 208, 4200-135 Porto, Portugal

³ Departamento de Biomedicina–Unidade de Biologia Experimental, Faculdade de Medicina, Universidade do Porto; Al. Prof. Hernâni Monteiro P- 4200 Porto, Portugal

* Correspondence: fanineto@med.up.pt (F.N.); isabmart@med.up.pt (I.M.)

† Both senior researchers contributed equally to the work and share the last authorship.

Abstract: Diffuse noxious inhibitory controls (DNIC), also known as conditioned pain modulation (CPM) in humans, is a paradigm wherein the heterotopic application of a noxious stimulus results in the attenuation of another spatially distant noxious input. The pre-clinical and clinical studies show the involvement of several neurochemical systems in DNIC/CPM and point to a major contribution of the noradrenergic, serotonergic and opiodergic systems. Here, we thoroughly review the latest data on the monoaminergic and opiodergic studies, focusing particularly on pre-clinical models of chronic pain. We also conduct an in-depth analysis of these systems, by integrating the available data with the descending pain modulatory circuits and the neurochemical systems therein, to bring light into the mechanisms involved in the regulation of DNIC. The most recent data suggest that DNIC may have a dual outcome encompassing not only analgesic but also hyperalgesic effects. This duality might be explained by the underlying circuitry and the receptor subtypes involved therein. Acknowledging this duality might contribute to validate the prognostic nature of the paradigm. Additionally, DNIC/CPM may serve as a robust paradigm with predictive value for guiding pain treatment through more effective targeting of descending pain modulation.

Keywords: conditioned pain modulation; descending pain modulation; noradrenaline; serotonin; opioids; brainstem; chronic pain

1. Introduction

The concept of diffuse noxious inhibitory control (DNIC) first appeared in the field of pain research through the studies of Le Bars et al [1-5]. DNIC is known as a paradigm of endogenous analgesia that is driven by the “pain inhibits pain” principle. This experience occurs when an additional painful stimulus, in one part of the body, suppresses the initial spatially distant experienced pain [6,7]. In the literature, this phenomenon is also mentioned as counter-irritation or heterotopic noxious counter-stimulation [6]. DNIC involves supraspinal circuitries that encompass several cortical areas identified in human imaging studies [8], along with brainstem regions involved in descending modulation [9].

In humans, DNIC is commonly known as conditioned pain modulation (CPM), which is the psychophysical paradigm based on quantitative sensory tests to assess the functionality of endogenous pain inhibition [10]. In these tests, two stimuli are applied to the patient: (1) a test noxious stimulus; (2) and a second conditioning painful stimulus applied in a distant (usually contralateral) region of the body. The test stimulus is done either at the same time or after the conditioning stimulus has ended [6]. The typology of stimuli used for DNIC/CPM testing is broad (thermal, mechanical). The nature of the test stimulus and conditioning stimulus may be of the same type (i.e., thermal conditioning and test stimulus) or there may be different modalities (i.e., thermal test stimulus and mechanical conditioning stimulus) [7,11]. Interestingly, the literature also indicates that it is possible

to generate a DNIC/CPM response without a painful stimulus, through the application of a strong non-noxious stimulus that is easily detected by nociceptors [12,13]. In healthy individuals, the intensity of pain evoked by the test stimulus usually decreases with the application of the conditioning stimulus, echoing a healthy and fully functional descending inhibitory nociceptive system [7]. The effect of CPM in humans is long-lasting and may withstand for up to 10 minutes [6]. In preclinical research, DNIC is evaluated in rodents in a similar form than in clinical settings. The animals can be studied awake or in the anesthetized state, depending on the aim of the experiment (i.e., for electrophysiology studies animals must be anesthetized) [11]. In rats, the effect of DNIC may last for at least one hour [14]. Furthermore, DNIC/CPM responses are dependent on many interindividual factors [7,15], including age and gender [16,17], anxiety [18,19] and depressive [20] states and genetic variations in the serotonergic 5-HTTLPR long allele [21] and in the opioidergic allele OPRM1 rs589046T [22].

The results of CPM evaluation have been described as a prognostic tool for the development of chronic pain in healthy individuals and as a predictor of chronic pain outcomes in diseased patients [23]. The use of CPM as a prognostic biomarker for the development of chronic pain has been widely discussed and is a little controversial [24,25]. Nonetheless, Dursteler *et al.* (2021) showed that patients with low preoperative CPM analgesia have a higher probability of developing persistent pain after surgery [26]. In the same clinical context, Larsen *et al.* (2021) further demonstrated that an impaired CPM analgesia may predict long-term postoperative pain even 12 months after surgery [27]. Despite these data, some clinicians question the prognostic validity of CPM as a predictor of nociceptive outcomes. Such controversy is related with the existence of different protocols for the CPM test with a wide variety of applied stimuli, which may cause lack of consistency in the results [28]. Notwithstanding, CPM was found to be reliably low in patients with chronic pain conditions, such as irritable bowel syndrome [29,30], migraine and tension-type headache [31-33], temporomandibular joint disorders [29,34], fibromyalgia [35] and osteoarthritis [36-38]. Additionally, Lewis *et al.* (2012) reported that approximately 70% of the studies comparing healthy individuals and patients with chronic pain demonstrated a significant reduction of CPM analgesia in patients [39]. Therefore, CPM may be a clinically significant parameter that may be added to the arsenal of diagnostic tools [28]. In addition to that it may also be used as therapeutic approach; a recent device harnessing CPM analgesia is being currently used for the treatment of migraine [40].

CPM has also been referred to as having much potential to serve as a useful predictor of the response to therapeutic treatment in patients with chronic pain. Studies with duloxetine, a **serotonin** (or 5-hydroxytryptamine; 5-HT) and **noradrenaline (NA) reuptake inhibitor**, in patients with painful diabetic polyneuropathy revealed that a more efficient CPM predicted better drug efficacy. Moreover, in the same study, CPM was improved and restored after treatment [41]. Similar observations were obtained regarding the analgesic tapentadol, which combines mu-opioid receptor agonism with NA reuptake inhibition [42]. As these drugs act on the descending modulatory system, CPM may also be viewed as an indicator of the integrity of this system. Thus, the assessment of CPM may guide clinical decisions and provide helpful information about the analgesic efficacy of a certain treatment according to the patient's nociceptive profile [28].

Overall, the evidence supporting the relevance and usefulness of CPM/DNIC in clinical settings appears to be solid. Although the number of preclinical studies focusing on the mechanisms that underlie DNIC have increased in recent years, this paradigm mostly remains understudied. In this review, we focused on the current state-of-art regarding DNIC mechanisms in pre-clinical models of chronic pain.

2. DNIC/CPM in Chronic pain

Multiple studies have described the loss of efficiency of CPM/DNIC analgesia in long-term pain [6,7,11,28,39]. Neuropathic pain from various causes, such as chemotherapy-induced neuropathy [43] and spinal cord injury [44], has been associated with less efficient CPM. Patients with fibromyalgia present abnormalities in muscles or joints that are accompanied by severe pain and abnormal CPM modulation [35,45]. Studies involving patients with osteoarthritis demonstrated that CPM is also lost

in this condition [36,38,46]. Interestingly, following a pain-relief surgery and reassessment of these patients, the normal pressure pain modulation was reinstated, suggesting CPM had been restored [38]. A study simultaneously exploring CPM in irritable bowel syndrome and temporomandibular joint disorders showed increased sensitivity to heat pain and loss of CPM analgesia in these conditions [29]. In patients with diabetic polyneuropathy, migraine and low back pain the studies show a more complex scenario with mixed results [47-50]. Lower analgesic or even hyperalgesic CPM responses were found in patients with migraine compared to healthy controls [31,33,51]. Improved CPM analgesia was found with duloxetine treatment in migraine [52]. In diabetic polyneuropathy while some studies found that CPM analgesia was restored both by duloxetine [41] or tapentadol treatment [42], recent studies found discrepancies in CPM efficacy within different cohorts of patients [47,53]. In fact, less effective CPM was associated with a shorter chronic pain duration [53] and CPM analgesia was more efficient among patients with painful diabetic polyneuropathy when compared with those in which the disease does not elicit pain [47]. This is most likely caused by altered sensory input in the tested affected body regions, suggesting that the assessment of pain modulation in patients with neuropathy should be performed in intact sites [47]. In patients with migraine a variety of CPM paradigms have been applied with mixed results [49]. However, CPM protocols using cold stimuli as an heterotopically applied condition stimulus have revealed the most unanimous results [31,33,51]. This reveals the importance of standardizing CPM protocols. Indeed, different methodologies have been used in the CPM/DNIC paradigms, including the location of the application of noxious stimuli, and type of the test- and conditioning-stimuli, which often makes the comparison between protocols difficult [28]. In agreement, experts in the field call for the standardization of CPM protocols in humans [54].

The few preclinical studies with rodents' models of chronic pain show DNIC loss after pain chronification. Indeed, rats with early-stage monoiodoacetate-induced osteoarthritis presented a normal DNIC, while at later stages of the condition DNIC became abolished [55]. Our studies using the complete Freund's adjuvant (CFA)-induced model of monoarthritis (MA) revealed a detailed temporal profile of DNIC analgesia progression. The DNIC analgesic responses were sustained from day 7 to day 21 of MA, peaked at day 28, and then progressively declined on days 35 and 42, eventually being completely lost at this later timepoint [56-58]. A previous study by Danzinger et al. (1999) analyzed the progression of DNIC in CFA-induced MA, but the experimental period has not gone beyond the 28 days of disease [59]. Impairment of DNIC analgesia and/or loss of wide dynamic range (WDR) neurons inhibition have been reported in animals with peripheral [17,60-65] and central [66-68] neuropathic pain. This loss in DNIC seems to be associated with the chronification of pain and a subsequent imbalance between the descending facilitation and inhibition, as demonstrated by studies pharmacologically manipulating the monoaminergic and opioidergic systems, which indicates that these pain modulatory systems play a crucial role in DNIC.

3. DNIC and the Descending Modulation of Pain

3.1. Descending Pain Modulation

Descending pain modulation refers to the process by which the brain and spinal cord regulate the perception of pain. It involves a complex network of neural pathways that originate in the brain and extend down to the spinal cord, where they contribute to either enhance or inhibit the transmission of pain signals [69,70]. The most thoroughly understood descending modulatory pathways emanate from the Periaqueductal gray area (PAG), the Rostral ventromedial medulla (RVM), the *Locus coeruleus* (LC), and the Dorsal reticular nucleus (DRt) [71,72]. Top-down modulation from the PAG is relayed by the RVM and the LC, with opioids playing a significant role in this process [71]. Descending pathways from the RVM can either inhibit or facilitate nociceptive transmission in the spinal cord. This bidirectional modulation is due to RVM neurons associated with pronociceptive ON- and antinociceptive OFF-cells. The LC also has a complex role in pain modulation, with both facilitatory and inhibitory effects on nociception; it facilitates pain through its ascending projections to various supraspinal areas [73-76] and inhibits pain through its descending projections to the spinal

cord [77]. The DRt is a medullary area notable for its descending facilitation of nociceptive transmission through reciprocal excitatory connections with the spinal dorsal horn [78,79]. The DRt is also a relay for descending noradrenergic facilitation of pain from the LC [73,74,76,80]. The opioidergic system can directly and indirectly modulate the spinal-DRt-spinal circuitry [81-83]. This opioidergic modulation at the DRt is clinically relevant [72,84,85] and is involved in DNIC [4,5,14,57,58,63]. Several supraspinal areas, such as the prefrontal cortex and the amygdala, are linked to the emotional and cognitive components of pain and indirectly influence the regulation of the PAG-RVM circuit and LC through the opioidergic and monoaminergic systems. The modulation of the PAG-RVM circuit involves opioidergic influences from upstream brain structures, such as the prefrontal cortex, anterior cingulate cortex, and amygdala [72]. Specifically, this opioidergic influence is crucial for maintaining pain homeostasis [86,87]. Additionally, the functional dichotomy of the LC in pain modulation involves rostral projections to the anterior cingulate cortex and amygdala in the modulation of anxiety-like behaviors in rodents [77].

Opioids play a major role in top-down modulation from the PAG, the RVM, LC and the DRt. Remarkably, the PAG-RVM circuit is essential for the expression of μ -opioid receptors (MOR)-mediated analgesia through disinhibition of γ -aminobutyric acid (GABA) interneurons [71,72,88]. In addition, at the RVM, opioids produce antinociception via direct inhibition of ON-cells, which express MOR, and indirect activation (i.e. disinhibition) of OFF-cells [89]. ON-cells have a well-established role in the maintenance of the sensory dimension of pain [90]. A recent study also found a crucial role for these cells in the maintenance of the affective dimension of chronic pain [91]. The neurochemical characterization of OFF- and ON-cells is starting to be uncovered. Neurons that functionally correspond to MOR-expressing ON-cells are GABAergic and project onto preproenkephalin-positive interneurons in the dorsal horn [92]. Neurons functionally corresponding to OFF-cells co-express GABA and preproenkephalin, and directly project onto nociceptor terminals in the dorsal horn to inhibit nociceptive transmission [93]. Interestingly, a recent study using advanced methodologies suggested the existence of an excitatory monosynaptic pathway involving brain-derived neurotrophic factor (BDNF)-expressing neurons at the RVM connected to inhibitory spinal galanin-positive neurons [94]. The authors suggest that morphine-induced antinociception is mediated by this pathway rather than by the presynaptic inhibition of primary afferents [94].

In the LC, opioids have a bidirectional role in the control of the descending noradrenergic modulation. They produce antinociception through disinhibition of NA neurons projecting to the spinal cord [72,95]. Opioids can also act through postsynaptic inhibitory (hyperpolarization) actions [96] and the hyperpolarization of LC neurons projecting to the spinal cord has been shown to produce hyperalgesia [97]. Additionally, opioids can also suppress the descending noradrenergic pain inhibition through a PAG-LC pathway [98]. Moreover, the effect of endogenous opioids in descending pain modulatory areas is also dependent on the opioid receptors (OR) expressed therein [72]. Unlike delta (δ ; DOR) activation, which yields effects similar to MOR, kappa (κ ; KOR) and nociceptin (NOP) produce divergent effects [72]. A role for the different isoforms expressed from MOR has more recently been uncovered [72,85]. The opioidergic receptors are guanine nucleotide-binding (G)-protein coupled receptors [99]. The canonical MOR isoform more often binds to inhibitory Gi-proteins, which reduces neuronal activation and generates analgesia [72,99]. Contrastingly, MOR coupling to the stimulatory Gs protein shifts MOR signaling towards neuronal excitation, which has been associated to morphine-induced tolerance and hyperalgesia [72,100]. MOR coupling with the Gs protein is mediated through some MOR isoforms, such as C-terminal splice variants [100] and a N-terminally truncated 6-TM isoform [101]. The switch of MOR signaling to excitatory occurs in the PAG where it is involved in tolerance [85,102]. At the DRt, the shift of MOR signaling from inhibitory to excitatory, during chronic morphine infusion or chronic inflammatory pain, contributes to opioid-induced hyperalgesia [85] and to switch DNIC analgesia to hyperalgesia [58], respectively.

A bidirectional control on the spinal nociceptive transmission is also mediated through the release of NA and 5-HT from the LC and RVM, respectively. NA is released at the spinal cord and can have both inhibitory (antinociceptive) and facilitatory (pronociceptive) effects on pain

transmission by acting through spinal alpha-2 adrenergic receptors (a2AR) or alpha-1 adrenergic receptors (a1AR) [103], respectively. A recent study also suggested inhibitory (antinociceptive) effects through the activation of a1AR [104]. The release of 5-HT at the spinal cord may also have either an antinociceptive or a pronociceptive effect, depending on the serotonergic receptors (5-HTR) expressed [105,106]. The 5-HTRs are categorized into seven families: 5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HT5, 5-HT6, and 5-HT7. Among these, 5-HT1R, 5-HT2R, 5-HT3R, and 5-HT7R are involved in the nociceptive pathway. The 5-HT1R, coupled to the inhibitory Gi/o protein, reduces cyclic adenosine monophosphate (cAMP) levels, generating both anti- and pronociceptive effects. The 5-HT2R, coupled to the Gq/11 protein, increases inositol trisphosphate (IP3) and diacylglycerol (DAG) levels upon activation, resulting in an antinociceptive effect. The 5-HT7R, coupled to a stimulatory Gs protein, increases cAMP levels upon activation, producing both pro- and antinociceptive effects. Unlike the other receptors, the 5-HT3R is a ligand-gated cation channel that depolarizes the neuronal membrane when activated, causing antinociception but also maintaining painful stimuli [105]. Upon 5-HT release in a certain neuronal location, all serotonergic receptor types are activated simultaneously, instigating a mixture of excitatory and inhibitory regulatory effects.

The main objective of descending nociceptive modulation is to adjust the organism to the environment, and this is dependent on a constant balance between descending inhibition and facilitation [90]. In an acute stress response (fight or flight), for example, there is higher activation of NA neurons in the LC and an increase in both the synthesis and release of this neurotransmitter, which reduces the feeling of pain and fear and allows the individual to flee from distressful situations [107]. Moreover, on healthy individuals, the inhibitory pain mechanisms are usually more prominent than the facilitatory inputs, resulting in the attenuation of pain. DNIC analgesia likely reflects this homeostatic state. When this balance is disrupted towards pain facilitation, there is no alleviation of pain sensation and chronic pain settles in [72,88,90]. During this event, the ongoing chronic noxious input may lead to many neuroplastic changes throughout the nervous system that inexorably foster the perfect environment for the onset of a chronic pain condition, affecting negatively the pain descending modulation mechanisms, which may be reflected by DNIC analgesia impairment.

3.2. DNIC Circuits Overlap with the Circuits Mediating Descending Pain Modulation

DNIC has been known for many years as an endogenous inhibitory paradigm. This phenomenon was first observed by Le Bars *et al.*, which demonstrated that when DNIC was activated through the application of a heterotopic noxious conditioning stimulation, the electrophysiological activity of the spinal WDR neurons located in lamina V was depressed [4,5]. In these studies, Le Bars *et al.* reported that DNIC effects are exclusive for these types of convergent neurons, since the application of a conditioning stimulus does not exert the same effect on noxious, non-noxious and proprioceptive cells. Further studies also showed that DNIC mechanisms seem to occur post-synaptically at the spinal cord, as the effect of the application of spinal glutamate was strongly inhibited upon the presence of a conditioning stimulus [108]. In addition, DNIC can only be activated by noxious stimulation, as non-noxious stimuli did not inhibit the electrophysiological activity of the WDR neurons at spinal lamina V [4]. Interestingly, the involvement of A delta- or A delta- and C-peripheral fibers in DNIC was later confirmed in another study, where the pharmacological blockade of the spinal nerves conducting either the test stimulus or the conditioning stimulus decreased DNIC intensity [109]. As a result of these findings, the many studies that ensued focused on understanding the physiological implications and the possible neurochemical mechanisms behind the DNIC paradigm [26,35,55,60,61,68].

The potential circuitries that underly DNIC analgesia have been a complete mystery since the first time this paradigm was reported. While initially it was believed that DNIC could be a phenomenon circumscribed to the spinal cord [4,5], it is now known that it involves “bottom- up” pathways that ascend through the ventrolateral funiculus [10,110,111] and return to the spinal cord through the dorsolateral funiculi [112]. The ascending projections of the superficial dorsal horn that are key in the transmission of DNIC information seem to rely on neurokinin-1 (NK1) receptors [113-115]. The NK1-positive neurons project to the parabrachial region [11,114,116], which in turn has

projections to PAG [117]. Spinal NK1 positive neurons are innervated by 5-HT_{3R} fibers [118], suggesting that they are modulated by descending serotonergic inputs. The descending serotonergic modulation through 5-HT_{3R} has been implicated in DNIC [57,61,68]. Our recent findings suggest a role for spinal 5-HT_{3R} not only in the top-down modulation of DNIC but also in a bottom-up circuit, likely encompassing NK1 positive neurons, that is involved in the trigger of DNIC [57].

The involvement of supraspinal circuits in the mechanisms of DNIC was further supported by several other studies. Le Bars *et al.* showed that DNIC inhibition of WDR neurons was not observed in animals that underwent cervical transection [4,119,120]. Additionally, DNIC responses were not detected in tetraplegic animals or patients with sectioned spinal cords [111,120]. Further studies investigated the involvement of several brainstem, subcortical and cortical areas. Villanueva *et al.* demonstrated that the thalamus is unlikely to be involved in DNIC circuitries, as both patients and animals with thalamic lesions exhibited no changes in DNIC [111,120,121]. The earlier studies investigating the involvement of some medullary and mesencephalic regions on DNIC have not always showed consensual data. While several works have reported that lesions of the PAG, parabrachial -cuneiform nucleus area, LC and RVM are not directly responsible for significant changes in DNIC responses [122,123], pharmacological studies [124-126] showed different findings. Regarding the RVM, a more recent study demonstrated the involvement of OFF-cells of the nucleus raphe magnus in DNIC analgesia [127]. The A5 noradrenergic nucleus is involved in descending DNIC analgesia as well, as suggested by the work showing that DNIC responses were abolished upon inhibition of spinally projecting A5 neurons [128]. The involvement of the LC in DNIC analgesia is also indicated by recent studies where the lesion of the LC compromised DNIC analgesia in naïve animals [67]. Additionally, the chemogenetic stimulation of the LC restored the impaired DNIC analgesia in rats with traumatic brain injury [66], further emphasizing the participation of this area in the descending noradrenergic modulation of DNIC analgesia. Recent optogenetic studies suggest a more complex scenario [104], due to the modular organization of the nucleus [77]. In fact, Kucharczyk *et al.* (2022) showed that the optoactivation of the ventral LC's module, which projects to the spinal cord [77], abolished DNIC, while a minor effect was obtained following optoactivation of the entire LC [104]. The authors suggest that the dorsal LC has either no effect or facilitates DNIC, while the ventral LC module inhibits DNIC [104]. Therefore, in the LC, two opposing circuits seem to coexist, one mediating descending inhibition of WDR neurons, reflecting DNIC analgesia, and a discrete LC-spinal circuit, originated in a ventral cerulean neuronal population, that abolishes DNIC (Figure 1).

The impact of the DRt on DNIC has also been recognized [78]. It was suggested by Le Bars *et al.* (2002) that DNIC triggered from the DRt could be part of a mechanism involved in the extraction of nociceptive information by depressing background body sensory activity, and therefore descending inhibitory inputs from the DRt may constitute a separate type of inhibitory control [129]. Nonetheless, the DRt seems to be a crucial relay station of DNIC, acting through its direct and reciprocal projections to the spinal cord [110,130]. This circuitry is modulated by opioids acting locally on DRt spinally-projecting neurons [14,58,63,82]. The DRt seems to also be a key ascending relay for DNIC trigger, namely through the activation of noradrenergic nuclei, as suggested by Kucharczyk *et al.* (2022) [104].

Several cortical and limbic regions, such as the Anterior cingulate cortex (ACC) and amygdala also influence DNIC responses [8,62,64,131,132]. For example, Navratilova *et al.* (2020) showed that injecting a MOR agonist into the right central nucleus of amygdala restored DNIC in a neuropathic pain rat model [62]. These results, together with the fact that limbic areas are directly connected to DNIC-associated brainstem regions, such as the LC, RVM and DRt, might account for the impact that psychological and emotional factors seem to have in the DNIC paradigm.




Figure 1. Proposed circuitry involved in the mediation of DNIC analgesia (red arrows; +DNIC), loss of DNIC analgesia (black arrows; -DNIC) and DNIC hyperalgesia (purple arrows). In the locus coeruleus (LC), two opposing circuits coexist. The first is an excitatory module, originating from dorsal LC neurons projecting to the spinal cord, which mediates DNIC analgesia. The second is an inhibitory module from ventral LC neurons projecting to spinal cord neurons, which abolishes DNIC. Both circuits exert their opposing effects through excitatory alpha-1 adrenergic receptors ($\alpha 1AR$), likely located on excitatory or inhibitory (GABA) spinal cord interneurons, impinging on spinal wide dynamic range (WDR) neurons, to mediate either the loss of DNIC or DNIC analgesia, respectively. In the A5 region, noradrenergic (NAergic) neurons projecting to the spinal cord contribute to DNIC analgesia by activating inhibitory alpha-2 adrenergic receptors ($\alpha 2AR$), likely located on spinal WDR neurons. In the rostral ventromedial medulla (RVM), serotonergic (5-HT) neurons project to either inhibitory GABAergic or excitatory spinal interneurons. Depending on the type of interneurons involved and receptors therein, this results in either DNIC analgesia or its abolishment. DNIC loss is probably mediated by the excitatory 5-HT3 receptors (5-HT3R) population that is most likely expressed on excitatory interneurons, while DNIC analgesia appears to be mediated by GABAergic interneurons that express both 5-HT3R and 5-HT7 receptors (5-HT7R). In this context, the effect of the 5-HT7R, which acts synergistically with $\alpha 2AR$, is likely to become more prominent and mediate DNIC analgesia. Pre-synaptic excitatory 5-HT3R are also found in peripheral afferent fibers (PAFs) originating from dorsal root ganglia (DRG) neurons, which synapse onto neurokinin-1 receptors expressing projection neurons (NK1+) in the spinal cord. These 5-HT3R are involved in a bottom-up circuit involved in DNIC initiation. In the dorsal reticular nucleus (DRt), the coupling of mu-opioid receptors (MOR) to either inhibitory (Gi) or stimulatory (Gs) G proteins determines whether DNIC analgesia or hyperalgesia occurs. This switch from inhibitory to excitatory signaling can disinhibit the descending facilitation from the DRt, contributing to the transition from DNIC analgesia, observed in physiological conditions, to hyperalgesia, as observed in chronic pain and prolonged opioid use. The concept of DNIC hyperalgesia challenges the established DNIC paradigm.

4. DNIC as a Descending Modulatory Mechanism: Neurochemical and Pharmacological Studies

Initial pharmacological studies implied the involvement of the descending opioidergic system in CPM/DNIC while more recent work further reports the involvement of the noradrenergic and serotonergic components. The unravelling of the contribution of each of these neurochemical systems to DNIC has had some major advancements over the past decades. The involvement of monoamines and opioids, together with that of other neurotransmitters, has been reviewed in pre-clinical [11] and clinical studies [133]. In the next section, we thoroughly analyze the latest data on the monoaminergic

and opioidergic studies, focusing particularly on pre-clinical models of chronic pain, and integrate this data in light of the functioning of the descending modulatory circuit (Figure 1).

4.1. Descending Serotonergic System

Early studies showed the importance of the serotonergic system in DNIC, by revealing that either the depletion of 5-HT [126] or blockade of 5-HT receptors [124] strongly decreased the inhibitory effects of DNIC upon WDR neurons activity, while a precursor of 5-HT potentiated it [124]. However, the specific contribution of this descending system to DNIC has been quite hard to unravel due to the wide variety of existing 5-HTRs, which can produce simultaneous facilitatory and inhibitory effects upon neuronal activity [88,105]. Additionally, the neurochemical studies evaluating the contribution of the serotonergic system to DNIC have focused mainly on the 5-HT_{3R} and 5-HT_{7R} types. The main studies are gathered in Table 1. The studies in healthy humans revealed a less conclusive involvement of the monoaminergic system in CPM [133]. However, in pathological chronic pain conditions where the descending pain modulatory system is impaired, which is reflected by a defective CPM analgesia [7], the available studies show a less ambiguous scenario. Indeed, in patients with diabetic polyneuropathy and migraine, the treatment with a 5-HT

NA reuptake inhibitor (duloxetine) improved CPM analgesia [41,52]. Similar findings were obtained when duloxetine was administered systemically in pre-clinical models of osteoarthritis, peripheral or central neuropathic pain [65,67,68]. Concerning the effects of selective 5-HT reuptake inhibitors (SSRIs), spinally administered citalopram and fluoxetine restored DNIC in a peripheral neuropathic pain model, while their systemic application yielded no results [60]. Thus, the data suggest that the effect of SSRIs on DNIC may potentially be dependent on the administration route and highlights the importance of specifically targeting spinal 5-HT receptors to restore DNIC.

The roles of spinal 5-HT_{7R} and 5-HT_{3R} on DNIC analgesia have been the most well studied until the present day [55,57,60,61,68,134]. In electrophysiological studies performed in the monoiodoacetate-induced osteoarthritis rat model, the blockade of spinal inhibitory 5-HT_{7R} reduced DNIC in the early stages of this condition, while the activation of these receptors restored DNIC during chronic stages [55]. The restoration of DNIC by citalopram and fluoxetine in the peripheral neuropathic pain model by Bannister et al., (2017) was reversed by 5-HT_{7R} antagonism [60]. This work suggests that 5-HT might exert an inhibitory action upon WDR neurons through the activation of 5-HT_{7R}, thus contributing to DNIC analgesia. Further confirming this hypothesis, DNIC analgesia was reversed by a 5-HT_{7R} antagonist in naïve rats [134]. However, the serotonergic input seems to act synergically with and be dependent on the noradrenergic input to restore DNIC analgesia, since the blockade of spinal α 2AR prevents DNIC restoration by SSRIs, at least following peripheral neuropathic pain [60]. The neurochemical data regarding the 5-HT_{7R} is scarce. The Lockwood et al. (2019) study in osteoarthritic rats showed that the levels of these receptors were unchanged in both the dorsal horn and dorsal root ganglia when DNIC was lost [55]. Regarding 5-HT_{3R}, our studies showed that the blockade of the excitatory spinal 5-HT_{3R} restored DNIC analgesia in a model of CFA-induced monoarthritis [57]. In agreement, following 5-HT_{3R} antagonism the inhibition of WDR neurons was increased in naïve animals and restored it in a rat model of peripheral neuropathy [61]. In the chronic joint inflammatory pain model, we also observed an increased expression of 5-HT_{3R} at a time of loss of DNIC analgesia. In this same study, an up-regulation of spinal 5-HT was also found, together with increased serotonergic activity, evaluated by the labelling of phosphorylated extracellular signal-regulated protein kinases 1 and 2 (pERK1/2), at the RVM [57]. This increased serotonergic activation at the RVM paralleled by an upregulation of spinal 5-HT has been previously reported in a rat model of neuropathic pain [135]. In contrast, in a model of traumatic brain injury, neither the antagonism of spinal 5-HT_{3R} [68] nor the spinal depletion of serotonergic fibers [67] restored DNIC. Additionally, in this model, increased levels of spinal 5-HT were found [68] and the systemic administration escitalopram restored DNIC [67,68]. Few studies have been conducted to explore the role of the other 5-HTR in DNIC. In naïve rats, the inhibitory effects of DNIC upon WDR neurons activity were diminished by the blockade with metergoline, which acts upon several 5-HTR subtypes, including 5-HT_{1R}, 5-HT_{2R}, 5-HT_{6R} and 5-HT_{7R} [124]. In a pioneer work establishing a

behavioral correlate for DNIC, the authors found that antagonizing 5-HT_{2R} with cinanserin blocked the potentiation of DNIC analgesia produced by a 5-HT precursor [136]. These results are in agreement with a strong reduction of the inhibitory effects of DNIC on WDR neurons activity produced by cinanserin [124]. The antagonism of 5-HT_{1AR} in naïve animals reduced DNIC analgesia [137]. In a model of medication overuse-induced migraine, the continuous exposure to a high dose of the 5-HT_{1R} agonist sumatriptan followed by noxious stimulation induced loss of DNIC analgesia, while a low dose had no effect [138].

The serotonergic input is involved in DNIC analgesia through 5-HT_{7R} [60,134]. The role that 5-HT_{7R} might play in DNIC is consistent with their location at the spinal cord where they are mainly expressed postsynaptically in local interneurons of the superficial dorsal laminae and presynaptically in peptidergic fibers [105]. Additionally, immunocytochemical studies showed 5-HT_{7R} co-localization with GABAergic neurons at the spinal dorsal horn [139]. Thus, given the excitatory action of 5-HT_{7R} [105] they might exert an inhibitory action upon WDR neurons through the activation of spinal inhibitory GABAergic interneurons. Additionally, in chronic inflammatory and peripheral neuropathic pain models, the serotonergic input contributes to abolish DNIC analgesia via the activation of 5-HT_{3R}. At the spinal cord, 5-HT_{3R} are in presynaptic terminals and postsynaptic interneurons of the superficial dorsal horn layers [105]. Postsynaptically, 5-HT_{3R} are positioned in inhibitory GABAergic interneurons, through which they exert antinociceptive effects [140], and in excitatory interneurons and terminal fibers apposing onto spinal NK-1 projection neurons [118]. The location of 5-HT_{3R} in excitatory interneurons and terminal fibers is likely responsible for facilitating nociceptive responses of some dorsal horn neurons [141,142]. Furthermore, the ascending nociceptive circuit is composed of NK1 expressing neurons [114,116], which are also involved in triggering DNIC [114]. These NK1+ neurons are innervated by either dense or sparse 5-HT_{3R} fibers [118]. In MA, the increased basal levels of 5-HT observed at 42 days, along with heightened 5-HT_{3R} expression [57], might cause a shift in the recruitment of the differentially 5-HT_{3R}-innervated NK1 neurons, thus contributing to the maintenance of persistent pain [105]. In face of 5-HT_{3R} pronounced pronociceptive effects, how to reconcile the restitution of DNIC by SSRIs? This can only be explained if the inhibitory effect of the 5-HT_{7R} becomes more prominent, therefore restoring DNIC [55]. Though the 5-HT_{3R} might indeed play a crucial facilitatory role in the ablation of DNIC analgesia in chronic pain, other mechanisms are at play. Studies in the brain indicate that SSRIs action upon 5-HT_{3R} often involves modulation and inhibition of these receptors rather than their desensitization [143,144]. In traumatic brain injury, the serotonergic input to the spinal cord does not seem to contribute to abolish DNIC analgesia via spinal 5-HT_{3R}, as their blockade fails to restore DNIC [68]. The reduced sensitivity of α 2AR is more likely to be responsible for the loss of DNIC [68]. The increased spinal levels of 5-HT in this central neuropathic model [68], on the contrary, contributes to restore DNIC. However, the imbalance caused by the impairment of α 2AR sensitivity does not seem to be offset by an increase in spinal 5-HT. Whether or not the 5-HT_{7R} is implicated in this lack of 5-HT effect is not known as the studies on traumatic brain injury did not target this receptor type.

4.2. Descending Noradrenergic System

The contribution of the descending noradrenergic system to DNIC analgesia has been very well studied both neurochemically and pharmacologically. The different studies showcase the functional relevance of the effects of the descending noradrenergic inhibition, mostly through spinal α 2AR. Moreover, they indicate that a potential impairment of this modulatory system has an impact on DNIC analgesia extinction in chronic pain. Table 1 summarizes the main recent studies that focused on the noradrenergic system. DNIC is significantly attenuated by the α 2AR antagonists in normal healthy animals [55,61,65,67,68,128,134,137,145]. In electrophysiological studies, where DNIC is evaluated as the inhibition of WDR neurons, the blockade of spinal α 2AR also abolished DNIC in rats with early-stage osteoarthritis [55]. The activation of spinal α 2AR restored DNIC that had been lost in osteoarthritic rats at a late-stage of the disease [55]. Additionally, intrathecal reboxetine, a selective NA reuptake inhibitor, and tapentadol, which is a dual MOR agonist and NA reuptake inhibitor, reinstated DNIC in peripheral neuropathic pain rats [61] and late-stage osteoarthritis [55].

Concomitantly with the loss of DNIC analgesia at late stages of chronic joint monoarthritis, we found no changes in the spinal $\alpha 2$ AR protein levels [56]. Coincidentally, the mRNA expression of the receptor remained unchanged at the spinal dorsal horn and lumbar dorsal root ganglia in the late stage of osteoarthritis induced by monoiodoacetate [55]. Moreover, we found a downregulation of spinal NA along with increased spinal levels of dopamine beta-hydroxylase (DBH) and increased neuronal activity in the LC at the same time point of disease [56]. This suggests that activation of the descending noradrenergic system likely compensates for the increased need of spinal NA by recruiting the biosynthetic machinery [56]. These findings also indicate that there is a counteracting attempt to regain DNIC analgesia at the spinal level during prolonged stages of chronic pain. However, the compensatory mechanisms may not always occur through significant changes in the expression of the receptor, but rather in its functionality. In accordance, in the CFA model of chronic joint inflammatory pain, we found that the spinal $\alpha 2$ AR were potentiated when DNIC analgesia was extinguished [56]. In addition to this spinal compensatory mechanism, other supraspinal events may be involved. Indeed, we also observed increased levels of neuronal activity, evaluated by the labelling of pERK1/2, in areas associated with the processing of the emotional component of pain, such as the basolateral amygdala and the ACC [56], that project to and receive projections from the LC [146,147]. In central neuropathic pain induced by traumatic brain injury, DNIC analgesia was also found impaired [66-68]. In this model, no significant differences in the levels of spinal NA were observed, but the spinal $\alpha 2$ R sensitivity was reduced [68]. This may explain why systemic administration of reboxetine failed to restore DNIC analgesia in these animals [67,68].

The contribution of alpha adrenoreceptors to the inhibition of WDR neurons seems to differ according to the noradrenergic cell group involved. In fact, recent work by Kucharczyk *et al.* shows that the optoactivation of either the A5 or the LC results in the inhibition of WDR spinal neurons, through $\alpha 2$ AR [128] or $\alpha 1$ AR [104], respectively. Given the opposite effects on neuronal excitability of both receptors, the effect of $\alpha 1$ AR is likely indirectly mediated through GABAergic inhibitory interneurons [148-150]. During the application of the DNIC paradigm, it is well established that the inhibition of WDR neurons is mediated through $\alpha 2$ AR [11,128]. The direct A5-spinal cord projection seems to play a key role in the mediation of this effect [128]. In the LC, the recently showed inhibitory and facilitatory modules for DNIC regulation seem to both mediate their effects through $\alpha 1$ AR [66,104]. Given the excitatory action of the $\alpha 1$ AR, this apparently surprising effect can only be explained by the localization of the receptor in dichotomic neuronal populations. Besides its putative action on GABAergic inhibitory interneurons, electrophysiological and pharmacological data also suggest that $\alpha 1$ AR can enhance the activity of both excitatory interneurons and projection neurons of the spinal dorsal horn [70,151].

4.3. Descending Opioidergic System

The opioidergic contribution to DNIC mechanisms was one of the very first findings that emerged in the initial studies with the paradigm in clinical trials [152,153]. However, the subsequent studies in humans are divisive on establishing the exact role for the descending opioidergic system in DNIC, as reviewed recently [133]. This emphasizes the complexity of the mechanisms entailing the participation of the opioidergic system in DNIC. In rodents, this association has been reported multiple times (Table 1). In initial electrophysiological studies it was reported that systemic and intracerebroventricular morphine inhibits DNIC [1,2,154] and that this effect was reversed by the administration of the opioid receptor antagonist naloxone [1,154]. The systemic injection of naloxone partially reduced DNIC [3]. The effects of naloxone found in electrophysiological studies were also behaviorally confirmed [136]. This pioneer work provided a clue about the involvement of the opioidergic system in DNIC. Later studies showed that systemic naloxone was able to revert DNIC analgesia, but this effect was dependent on the conditioning stimulus [145]. In painful conditions such as acute inflammation, systemic naloxone was also shown to prevent DNIC analgesia [14]. In contrast, the systemic administration of a specific KOR antagonist prevented the loss of behavioral DNIC analgesia in female rats with chronic orofacial pain [17]. In a model of medication overuse

induced migraine the continuous exposure to morphine abolished DNIC analgesia [138]. Altogether, these studies highlight the complexity of the opioidergic involvement in DNIC.

More recent studies have focused on a more targeted approach to the pharmacological administration of opioidergic receptor agonists and antagonists, with the injection of these drugs in specific opioidergic-modulated supraspinal nuclei, such as the DRt, RVM and amygdala. Intra-DRt injection of naloxone blocked DNIC in sham rats [63]. Additionally, we have also found that DAMGO, a mu-opioid receptor agonist, at the DRt increased DNIC analgesia in normal healthy animals [58]. These studies reflect not only that DRt descending pathways are involved in DNIC, but also that these mechanisms require opioidergic signaling through MOR. Intra-DRt naloxone blocked DNIC analgesia in acute muscle pain [14], but did not produce any effects on DNIC in animals that had lost DNIC following spinal nerve ligation-induced neuropathic pain [63]. In chronic joint pain, we have shown that the activation of MOR at the DRt produced a hyperalgesic effect (*i.e.*, shifted DNIC analgesia to hyperalgesia) [58]. These latter findings suggest differential opioidergic signaling at the DRt in acute [14] *vs* chronic phases of inflammatory pain [58]. Additionally, the role of MOR-mediated modulation of DNIC at the DRt might differ in situations where DNIC is lost during inflammatory [58] or neuropathic pain [63]. Regarding the RVM, an early study showed that MOR activation at the Raphe Magnus has no effect on DNIC, when evaluated by the activity of spinal trigeminal nucleus oralis convergent neurons [155]. In agreement, a later study showed that naloxone into the RVM had no effect on DNIC analgesia in a model of acute muscle pain [14]. These results are puzzling, given the importance of the opioidergic modulation of ON- and OFF-cells in the RVM [72,89]. In addition, the inactivation of the RVM restored DNIC analgesia that had been lost following continuous exposure to morphine in a model of medication-overuse induced headache [156]. Therefore, there may be an opioid involvement in the modulation of DNIC by the RVM.

The opioidergic system also modulates DNIC through its action on MOR and KOR at the amygdala. In fact, either MOR activation [62] or KOR blockade [64] at the central nucleus of the amygdala restored DNIC analgesia [62] as well as the inhibition of WDR neurons [64] in a neuropathic pain rat model. Interestingly, both MOR and KOR signaling are involved in the modulation of the aversive/affective dimension of neuropathic pain and DNIC [62,157]. Therefore, DNIC is modulated by supraspinal areas involved in the affective component of pain and this is mediated by opioid signaling. Interestingly, we found a loss of DNIC that was concomitant with anxiodepressive-like behaviors and neuronal activation of supraspinal areas involved in the affective component of pain, including the amygdala, in a chronic pain model [56]. The effect that opioids have in DNIC, specifically at the spinal cord level, has been poorly investigated. However, the studies with tapentadol, through its effects on the opioidergic component, are perhaps the most suggestive of the opioidergic spinally mediated mechanisms. Tapentadol, which acts simultaneously as a MOR agonist and a NA reuptake inhibitor [42], restored DNIC in late-stage osteoarthritis [55] and spinal nerve ligation [61]. The effects of tapentadol are mostly attributed to a synergistic effect of MOR activation and inhibition of NA reuptake at the spinal cord [158]. Consistent with this effect, MORs are expressed in the spinal cord where they serve as an interface for ascending inhibition and descending opioidergic inhibition triggered from the PAG-RVM circuitry [72,159]. Indeed, endogenous opioid peptides are released from descending fibers, arising from the PAG-RVM circuitry, into the spinal cord [92,93]. The role of spinal MORs in the mediation of descending opioidergic inhibition is further corroborated by the conditional knockout of mu-opioid receptors in primary afferent neurons, which significantly reduced the analgesic effect induced by the activation of the PAG-RVM circuit [160].

The available molecular studies regarding the involvement of the opioidergic system on DNIC have been focused on the DRt. Recent studies have shown that during opioid-induced hyperalgesia, MOR activity at the DRt switches its coupling to the inhibitory Gi proteins towards excitatory Gs proteins, causing an up-regulation of the cAMP response element-binding protein (CREB) phosphorylation, which accounts for the hyperalgesia effects observed upon MOR activation [85]. In the CFA model of chronic joint pain, we have also found increased levels of phosphorylated CREB (pCREB) at a timepoint of disease evolution when DNIC analgesia is lost, and when the activation of MOR at the DRt produces DNIC hyperalgesia [58]. This effect is blocked by pretreatment with an

ultra-low dose of naloxone [58], which inhibits MOR coupling to the stimulatory Gs protein and restores its coupling to the inhibitory Gi [161]. This further reinforces the occurrence of a probable shift of MOR signaling at the DRt, which may likely contribute to the extinction of DNIC analgesia [58].

These studies, together with previous work evaluating MOR signaling at the DRt [84], indicate that in physiological conditions the opioidergic input to the DRt is necessary for the expression of DNIC analgesia. Thus, DNIC analgesia relies on the inhibition of descending facilitation from the DRt. This is further consistent with the inhibitory effects of MOR on neuronal excitability. Indeed, MOR activation at the DRt induces the intracellular coupling of these receptors to inhibitory Gi proteins, inhibiting the adenylyl cyclase and producing an analgesic effect [84]. In a neuropathic pain condition, in which DNIC is lost and MOR blockade does not alter the DNIC outcome [63], the tonic inhibitory opioidergic input is lost. This is likely due to the desensitization of MOR that occurs in neuropathic pain [84]. In chronic inflammatory pain, the switch of MOR signaling to excitatory disinhibits the descending facilitation from the DRt, contributing thus to switch DNIC from analgesia to hyperalgesia. Our results also likely uncovered a facilitatory pathway for DNIC, which has previously been postulated [134]. This pathway originates in the DRt and terminates in lamina V of the spinal dorsal horn [78,79], where WDR neurons are located and whose activity is enhanced by DRt activation [162].

Table 1. Summary of recent pharmacological studies performed in animals models of pain.

	5-HT STUDIES	NA STUDIES	OPIOID STUDIES
NORMAL HEALTHY ANIMALS	<ul style="list-style-type: none">• 5-HT3R blockade increases DNIC analgesia magnitude and WDR inhibition [57,61]• 5-HT7R blockade abolishes DNIC analgesia [134]• Spinal 5-HT1AR antagonism reduced DNIC analgesia [137]	<ul style="list-style-type: none">• a2AR blockade attenuates/abolishes DNIC analgesia and WDR inhibition [55,61,65,67,68,128,134,137,145]• LC lesion (neurotoxin) abolishes DNIC analgesia [67]• LC chemogenetic activation produces DNIC analgesia [66]• A5-SC optoinhibition abolishes DNIC (WDR neuronal inhibition) [128]• LC:SC optoactivation abolishes DNIC (WDR neuronal inhibition) through a1AR [104]	<ul style="list-style-type: none">• Systemic naloxone reverses DNIC analgesia induced by chemical but not electrical conditioning stimuli [145]• Systemic and intracerebroventricular naloxone reduced DNIC analgesia [137]• MOR activation at DRt increases DNIC analgesia [58]• Naloxone at the DRt abolishes DNIC [63]
INFLAMMATORY PAIN			
<i>Muscle inflammation</i> <i>DNIC was enhanced and similar in acute and chronic phases of inflammation</i>			<ul style="list-style-type: none">• Systemic naloxone abolished DNIC analgesia• Naloxone into the DRt abolished DNIC analgesia• Naloxone into the RVM had no effect on DNIC analgesia [14]
Early-stage osteoarthritis (Monoiodoacetate model)	<ul style="list-style-type: none">• Blockade of spinal 5-HT7R partially reduced DNIC (WDR neuronal inhibition) [55]	<ul style="list-style-type: none">• Blockade of spinal a2AR abolished DNIC (WDR neuronal inhibition) [55]	
Late-stage osteoarthritis (Monoiodoacetate model)	<ul style="list-style-type: none">• Activation of spinal 5-HT7R restored DNIC (WDR neuronal inhibition) [55]	<ul style="list-style-type: none">• Activation of spinal a2AR restored the DNIC (WDR neuronal inhibition)[55]	
Loss/attenuation of DNIC analgesia or	<ul style="list-style-type: none">• 5-HT7R levels unchanged in the dorsal horn and lumbar dorsal root ganglia [55]	<ul style="list-style-type: none">• a2AR levels unchanged in the dorsal horn and lumbar dorsal root ganglia [55]	

WDR neuronal inhibition	<ul style="list-style-type: none">Duloxetine improved DNIC analgesia [65]Tapentadol restored the DNIC (WDR neuronal inhibition) [55]
Intermediate stage of monoarthritis (CFA model) <i>Magnitude of DNIC analgesia peaked at an intermediate time point</i>	<ul style="list-style-type: none">No changes in spinal levels of DBHNo changes in spinal NA levels [56]
Late stage monoarthritis (CFA model) <i>Loss of DNIC analgesia</i>	<ul style="list-style-type: none">Increased spinal 5-HT levels [57]Blockade of spinal 5-HT3R restored DNIC analgesia [57]Increased spinal 5-HT3R expression [57]Increased RVM serotonergic activity (pERKs1/2 + TPH labelling) [57].Decreased spinal NA levelsIncreased spinal levels of DBH [56]Spinal a2AR potentiated [56]No changes in the spinal a2AR expression [56]Increased LC neuronal activity (pERKs1/2 labelling)Increased neuronal activity (pERKs1/2 labelling) in brain areas connected with the LC involved in the affective component of pain [56].MOR activation at DRt produces DNIC hyperalgesia<ul style="list-style-type: none">Blockade of MOR coupling to the excitatory Gs protein at the DRt restores DNIC analgesia [58]Decreased levels of MOR and increased pMOR at the DRtIncreased levels of pCREB at the DRt [58]
PERIPHERAL NEUROPATHY	
Spinal nerve ligation <i>Loss of DNIC analgesia and WDR neuronal inhibition</i>	<ul style="list-style-type: none">5-HT3R blockade restored DNIC (inhibition of WDR neurons) [61]Systemic citalopram and fluoxetine yielded no resultsSpinal application of citalopram and fluoxetine restored DNIC (inhibition of WDR neurons) through 5-HT7R and a2AR [60].Reboxetine restored DNIC (inhibition of WDR neurons) [61]Naloxone into the DRt had no effects on DNIC inhibition of WDR neurons [63]Systemic KOR blockade restored DNIC analgesia [64]KOR blockade at the central nucleus of the amygdala restored DNIC analgesia and WDR neuronal inhibition [64]Morphine at the ipsilateral central nucleus of the amygdala restored DNIC analgesia [62]Systemic KOR blockade prevented the loss of DNIC analgesia [17]
Partial sciatic nerve ligation <i>Attenuation of DNIC analgesia</i>	<ul style="list-style-type: none">Duloxetine improved DNIC analgesia [65]
Chronic constriction injury of the infraorbital nerve <i>Loss of DNIC analgesia in females</i>	<ul style="list-style-type: none">Tapentadol restored DNIC (inhibition of WDR neurons) [61]
TRAUMATIC BRAIN INJURY	<ul style="list-style-type: none">Spinal depletion of 5-HT fails to restore DNIC [67]LC chemogenetic activation restores DNIC through a1AR [66]

DNIC analgesia impaired	<ul style="list-style-type: none">• 5-HT3R blockade fails to restore DNIC [68]	<ul style="list-style-type: none">• Reduced spinal a2AR sensitivity [68]
	<ul style="list-style-type: none">• Systemic escitalopram restores DNIC [67,68]• Escitalopram restores DNIC; α2AR signaling is not involved [67]• Increased spinal 5-HT levels [68]	<ul style="list-style-type: none">• Reboxetine fails to restore DNIC analgesia [67,68]• Unchanged spinal NA levels [68]
	<ul style="list-style-type: none">• Duloxetine restores DNIC [67,68]	
MEDICATION OVERUSE-INDUCED MIGRAINE Loss of DNIC analgesia/ inhibition of medullary dorsal horn neurons	<ul style="list-style-type: none">• Continuous exposure to a low dose of the 5-HT1R agonist sumatriptan did not cause loss of DNIC analgesia [138]• Continuous exposure to a high dose of sumatriptan followed by noxious stimulation induced loss of DNIC analgesia two weeks after treatment cessation [138]	<ul style="list-style-type: none">• Continuous exposure to morphine caused opioid-induced hyperalgesia (OIH) and abolished DNIC analgesia both during and upon cessation of OIH manifestation [138]• Continuous exposure to morphine abolished DNIC and inactivation of the RVM restored DNIC [156]

Legend: 5-HT: 5-hydroxytryptamine (Serotonin); 5-HT3R: 5-hydroxytryptamine receptor type 3; 7-HT7R: 5-hydroxytryptamine receptor type 7; α1AR: Alpha adrenergicv receptor type 1; α2AR: Alpha adrenergicv receptor type 2; CFA: Complete Freund’s Adjuvant; CPM: Conditoned Pain Modulation; DBH: Dopamine beta-hydroxylase; DNIC: Diffuse Noxious Inhibitory Controls; DRt: Dorsal Reticular Nucleus; KOR: κ-opioidergic receptors; LC: *Locus Coeruleus*; MOR: μ-opioidergic receptors; NA: Noradrenaline; pCREB: Phosphorylated cyclic-AMP response element-binding protein; pERKs1/2: Phosphorylated extracellular signal-regulated protein kinases 1 and 2; pMOR: Phosphorylated μ-opioidergic receptors; RVM: Rostral Ventromedial Medulla; TPH: Tryptophan Hydroxylase; WDR: Wide Dynamic Range.

5. Is DNIC Only a Descending INHIBITORY/ANALGESIC Mechanism?

DNIC is a paradigm very commonly known for its endogenous analgesic nature. However, there is mounting evidence that DNIC responses may not always be analgesic. Indeed, the paradigm of CPM in humans can manifest as both hyperalgesia and analgesia [28,163-165]. Recent pre-clinical studies also suggest this duality. Two pathways emanating from the LC, that play opposing roles in DNIC, seem to coexist [104]. The variability of spinal 5-HTRs and their effects upon neuronal excitability may also contribute to the dual outcomes of the serotonergic pathways observed in DNIC. Additionally, Tansley *et al.* reported that the outcome of DNIC stimulation is dependent on the intensity of the test stimulus given to awake animals, so that the paradigm generated hyperalgesia with lower intensity stimuli and analgesia with a stronger stimulation [166]. In view of the later observations showing opposite effects in DNIC behavioral responses, some authors have suggested a review of DNIC nomenclature. Bannister *et al.* proposed that DNIC should refer only to the mechanistical changes observed in anesthetized animals, specifically indicating the inhibition of WDR neurons after a conditioning stimulus. Moreover, the term "descending control of nociception" (DCN) was suggested as being a better nomenclature for the behavioral correlate of DNIC in awake animals, in order to reflect the analgesic and hyperalgesic effects [163].

The duality of the DNIC/DCN nature brings a new set of unanswered concerns. Indeed, most preclinical studies show an ablation of DCN/DNIC analgesia in animals with chronic inflammatory or neuropathic pain, which is translated into a decrease of the intensity of response or the total

absence of DCN/DNIC analgesia, when compared to control groups. Considering the possibility of the existence of a hyperalgesic DCN, it is feasible to question if this absence of DCN/DNIC analgesia is, indeed, the real output of the behavioral evaluation of DNIC or, if it reflects, instead, a methodological limitation of the tools used so far to measure the variation of DCN/DNIC magnitude. If the later hypothesis is correct, then a serious review of all nociceptive behavioral assessment tools must be performed in order to determine which methods are the most adequate to detect lower or negative variations during the nociceptive behavioral evaluation of DCN/DNIC.

Nemoto *et al.* suggested that opposing neurochemical pathways may mediate the hyperalgesic and the analgesic DCN [134]. Our recent findings suggest that the DRt through its opioidergic regulation may be involved in mediating both the hyperalgesic and analgesic DNIC/DCN, and that these processes might be dependent on different molecular intracellular mechanisms. The branch of the DRt that projects to the spinal laminae V [78,79] and controls the activity of the WDR neurons [162] likely mediates DRt effects on DCN/DNIC. Supporting this, the tonic opioidergic inhibition of this branch, in normal conditions, allows the electrophysiological expression of DNIC [63]. Behaviorally, we showed that DCN/DNIC analgesia in healthy animals is enhanced when a selective agonist activates MOR located in the DRt [58]. At late-stage monoarthritis, we also found that MOR activation at the DRt causes DCN/DNIC analgesia to become hyperalgesic. This was due to a switch of MOR signaling at the DRt from inhibitory to excitatory, likely increasing the descending facilitation from the DRt [58]. This change may also be responsible for the extinction of DCN/DNIC analgesia in late-stage monoarthritis [58], which also happens in chronic pain patients [6,7,11,28,39].

6. Conclusions

DNIC is a mirror of descending modulation, encompassing both inhibitory and excitatory effects. Under normal conditions or acute pain, the inhibitory pathway is predominant, reflecting the analgesic nature of DNIC, which in turn indicates a balanced functioning of descending modulation. In this context, facilitatory pathways, such as those emanating from the DRt, are likely silenced by an opioidergic input. In chronic pain, the imbalance in descending modulation towards increased facilitation disinhibits/enhances these facilitatory pathways. One of the mechanisms through which these facilitatory pathways become disinhibited, entails the shift in opioidergic signaling at the DRt. Depending on the magnitude or nature of this disinhibition of the facilitatory effects, the outcome of DNIC may result in either a loss of analgesia or development of hyperalgesia.

The translational value of this paradigm suggests that assessing CPM in patients with pain could enable us to predict the effectiveness of certain drugs, offering a potentially valuable tool for determining the likelihood of treatment success. In fact, the use of opioids may not be ideal because both chronic pain and chronic treatment with opioids alter MOR signaling in facilitatory pathways, which results in the transformation of DNIC effects from analgesia or lack of analgesia to hyperalgesia, reflecting the maladaptation of the descending modulatory system. Therefore, opioids-based therapy is counterproductive since it may likely exacerbate this effect in some chronic pain conditions. On the other hand, serotonin and norepinephrine reuptake inhibitors (SNRIs) may represent a better therapeutic option. The serotonergic component of these drugs seems to be beneficial despite the marked pronociceptive role of 5-HT₃R activation in some chronic pain conditions. SSRIs appear to mitigate these 5-HT₃R effects while enhancing the antinociceptive effects of 5-HT₇R activation. Additionally, 5-HT₇R likely acts synergistically with α₂AR activation. Supporting this, clinical studies suggest that duloxetine, a dual reuptake inhibitor, is an effective approach for managing chronic pain.

Author Contributions: Conceptualization: Fani Neto (FN) and Isabel Martins (IM); Resources: Raquel Pereira-Silva (RPS), FN and IM; Data curation: RPS, FN and IM; Writing—original draft preparation: RPS; Writing—review and editing: FN and IM; Visualization: RPS, FN and IM; Funding acquisition: FN and IM. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Le Bars, D.; Chitour, D.; Kraus, E.; Clot, A.M.; Dickenson, A.H.; Besson, J.M. The effect of systemic morphine upon diffuse noxious inhibitory controls (DNIC) in the rat: evidence for a lifting of certain descending inhibitory controls of dorsal horn convergent neurones. *Brain Res* **1981**, *215*, 257-274, doi:10.1016/0006-8993(81)90506-0.
2. Le Bars, D.; Chitour, D.; Kraus, E.; Dickenson, A.H.; Besson, J.M. [Depression by morphine of various descending inhibitory controls modulating the transmission of nociceptive information at the spinal level in the rat]. *C R Seances Acad Sci D* **1980**, *291*, 433-436.
3. Le Bars, D.; Chitour, D.; Kraus, E.; Dickenson, A.H.; Besson, J.M. Effect of naloxone upon diffuse noxious inhibitory controls (DNIC) in the rat. *Brain Res* **1981**, *204*, 387-402, doi:10.1016/0006-8993(81)90597-7.
4. Le Bars, D.; Dickenson, A.H.; Besson, J.M. Diffuse noxious inhibitory controls (DNIC). II. Lack of effect on non-convergent neurones, supraspinal involvement and theoretical implications. *Pain* **1979**, *6*, 305-327, doi:10.1016/0304-3959(79)90050-2.
5. Le Bars, D.; Dickenson, A.H.; Besson, J.M. Diffuse noxious inhibitory controls (DNIC). I. Effects on dorsal horn convergent neurones in the rat. *Pain* **1979**, *6*, 283-304, doi:10.1016/0304-3959(79)90049-6.
6. Nir, R.R.; Yarnitsky, D. Conditioned pain modulation. *Curr Opin Support Palliat Care* **2015**, *9*, 131-137, doi:10.1097/SPC.0000000000000126.
7. Ramaswamy, S.; Wodehouse, T. Conditioned pain modulation-A comprehensive review. *Neurophysiol Clin* **2021**, *51*, 197-208, doi:10.1016/j.neucli.2020.11.002.
8. Youssef, A.M.; Macefield, V.G.; Henderson, L.A. Cortical influences on brainstem circuitry responsible for conditioned pain modulation in humans. *Hum Brain Mapp* **2016**, *37*, 2630-2644, doi:10.1002/hbm.23199.
9. Goubert, D.; Danneels, L.; Cagnie, B.; Van Oosterwijck, J.; Kolba, K.; Noyez, H.; Meeus, M. Effect of Pain Induction or Pain Reduction on Conditioned Pain Modulation in Adults: A Systematic Review. *Pain Pract* **2015**, *15*, 765-777, doi:10.1111/papr.12241.
10. Granovsky, Y. Conditioned pain modulation: a predictor for development and treatment of neuropathic pain. *Curr Pain Headache Rep* **2013**, *17*, 361, doi:10.1007/s11916-013-0361-8.
11. Kucharczyk, M.W.; Valiente, D.; Bannister, K. Developments in Understanding Diffuse Noxious Inhibitory Controls: Pharmacological Evidence from Pre-Clinical Research. *J Pain Res* **2021**, *14*, 1083-1095, doi:10.2147/JPR.S258602.
12. Granot, M.; Weissman-Fogel, I.; Crispel, Y.; Pud, D.; Granovsky, Y.; Sprecher, E.; Yarnitsky, D. Determinants of endogenous analgesia magnitude in a diffuse noxious inhibitory control (DNIC) paradigm: do conditioning stimulus painfulness, gender and personality variables matter? *Pain* **2008**, *136*, 142-149, doi:10.1016/j.pain.2007.06.029.
13. Pud, D.; Sprecher, E.; Yarnitsky, D. Homotopic and heterotopic effects of endogenous analgesia in healthy volunteers. *Neurosci Lett* **2005**, *380*, 209-213, doi:10.1016/j.neulet.2005.01.037.
14. de Resende, M.A.; Silva, L.F.; Sato, K.; Arendt-Nielsen, L.; Sluka, K.A. Blockade of opioid receptors in the medullary reticularis nucleus dorsalis, but not the rostral ventromedial medulla, prevents analgesia produced by diffuse noxious inhibitory control in rats with muscle inflammation. *J Pain* **2011**, *12*, 687-697, doi:10.1016/j.jpain.2010.12.009.
15. Hermans, L.; Van Oosterwijck, J.; Goubert, D.; Goudman, L.; Crombez, G.; Calders, P.; Meeus, M. Inventory of Personal Factors Influencing Conditioned Pain Modulation in Healthy People: A Systematic Literature Review. *Pain Pract* **2016**, *16*, 758-769, doi:10.1111/papr.12305.
16. Edwards, R.R.; Fillingim, R.B.; Ness, T.J. Age-related differences in endogenous pain modulation: a comparison of diffuse noxious inhibitory controls in healthy older and younger adults. *Pain* **2003**, *101*, 155-165, doi:10.1016/s0304-3959(02)00324-x.
17. Fiatcoski, F.; Jesus, C.H.A.; de Melo Turnes, J.; Chichorro, J.G.; Kopruszinski, C.M. Sex differences in descending control of nociception (DCN) responses after chronic orofacial pain induction in rats and the contribution of kappa opioid receptors. *Behav Brain Res* **2024**, *459*, 114789, doi:10.1016/j.bbr.2023.114789.
18. Cormier, S.; Piche, M.; Rainville, P. Expectations modulate heterotopic noxious counter-stimulation analgesia. *J Pain* **2013**, *14*, 114-125, doi:10.1016/j.jpain.2012.10.006.
19. Lindstedt, F.; Berrebi, J.; Greayer, E.; Lonsdorf, T.B.; Schalling, M.; Ingvar, M.; Kosek, E. Conditioned pain modulation is associated with common polymorphisms in the serotonin transporter gene. *PLoS One* **2011**, *6*, e18252, doi:10.1371/journal.pone.0018252.

20. Normand, E.; Potvin, S.; Gaumond, I.; Cloutier, G.; Corbin, J.F.; Marchand, S. Pain inhibition is deficient in chronic widespread pain but normal in major depressive disorder. *J Clin Psychiatry* **2011**, *72*, 219-224, doi:10.4088/JCP.08m04969blu.
21. Nahman-Averbuch, H.; Nir, R.R.; Sprecher, E.; Yarnitsky, D. Psychological Factors and Conditioned Pain Modulation: A Meta-Analysis. *Clin J Pain* **2016**, *32*, 541-554, doi:10.1097/AJP.0000000000000296.
22. Olesen, A.E.; Nielsen, L.M.; Feddersen, S.; Erlenwein, J.; Petzke, F.; Przemec, M.; Christrup, L.L.; Drewes, A.M. Association Between Genetic Polymorphisms and Pain Sensitivity in Patients with Hip Osteoarthritis. *Pain Pract* **2018**, *18*, 587-596, doi:10.1111/papr.12648.
23. Fernandes, C.; Pidal-Miranda, M.; Samartin-Veiga, N.; Carrillo-de-la-Pena, M.T. Conditioned pain modulation as a biomarker of chronic pain: a systematic review of its concurrent validity. *Pain* **2019**, *160*, 2679-2690, doi:10.1097/j.pain.0000000000001664.
24. Granovsky, Y.; Yarnitsky, D. Personalized pain medicine: the clinical value of psychophysical assessment of pain modulation profile. *Rambam Maimonides Med J* **2013**, *4*, e0024, doi:10.5041/RMMJ.10131.
25. Nuwailati, R.; Bobos, P.; Drangsholt, M.; Curatolo, M. Reliability of conditioned pain modulation in healthy individuals and chronic pain patients: a systematic review and meta-analysis. *Scand J Pain* **2022**, *22*, 262-278, doi:10.1515/sjpain-2021-0149.
26. Dursteler, C.; Salazar, Y.; Rodriguez, U.; Pelfort, X.; Verdie, L.P. Conditioned pain modulation predicts persistent pain after knee replacement surgery. *Pain Rep* **2021**, *6*, e910, doi:10.1097/PR9.0000000000000910.
27. Larsen, D.B.; Laursen, M.; Edwards, R.R.; Simonsen, O.; Arendt-Nielsen, L.; Petersen, K.K. The Combination of Preoperative Pain, Conditioned Pain Modulation, and Pain Catastrophizing Predicts Postoperative Pain 12 Months After Total Knee Arthroplasty. *Pain Med* **2021**, *22*, 1583-1590, doi:10.1093/pm/pnaa402.
28. Kennedy, D.L.; Kemp, H.I.; Ridout, D.; Yarnitsky, D.; Rice, A.S.C. Reliability of conditioned pain modulation: a systematic review. *Pain* **2016**, *157*, 2410-2419, doi:10.1097/j.pain.0000000000000689.
29. King, C.D.; Wong, F.; Currie, T.; Mauderli, A.P.; Fillingim, R.B.; Riley, J.L., 3rd. Deficiency in endogenous modulation of prolonged heat pain in patients with Irritable Bowel Syndrome and Temporomandibular Disorder. *Pain* **2009**, *143*, 172-178, doi:10.1016/j.pain.2008.12.027.
30. Song, G.H.; Venkatraman, V.; Ho, K.Y.; Chee, M.W.; Yeoh, K.G.; Wilder-Smith, C.H. Cortical effects of anticipation and endogenous modulation of visceral pain assessed by functional brain MRI in irritable bowel syndrome patients and healthy controls. *Pain* **2006**, *126*, 79-90, doi:10.1016/j.pain.2006.06.017.
31. Nahman-Averbuch, H.; Granovsky, Y.; Coghill, R.C.; Yarnitsky, D.; Sprecher, E.; Weissman-Fogel, I. Waning of "conditioned pain modulation": a novel expression of subtle pronociception in migraine. *Headache* **2013**, *53*, 1104-1115, doi:10.1111/head.12117.
32. Pielsticker, A.; Haag, G.; Zaudig, M.; Lautenbacher, S. Impairment of pain inhibition in chronic tension-type headache. *Pain* **2005**, *118*, 215-223, doi:10.1016/j.pain.2005.08.019.
33. Sandrini, G.; Rossi, P.; Milanov, I.; Serrao, M.; Cecchini, A.P.; Nappi, G. Abnormal modulatory influence of diffuse noxious inhibitory controls in migraine and chronic tension-type headache patients. *Cephalalgia* **2006**, *26*, 782-789, doi:10.1111/j.1468-2982.2006.01130.x.
34. Oono, Y.; Wang, K.; Baad-Hansen, L.; Futarmal, S.; Kohase, H.; Svensson, P.; Arendt-Nielsen, L. Conditioned pain modulation in temporomandibular disorders (TMD) pain patients. *Exp Brain Res* **2014**, *232*, 3111-3119, doi:10.1007/s00221-014-3997-7.
35. Staud, R. Evidence for shared pain mechanisms in osteoarthritis, low back pain, and fibromyalgia. *Curr Rheumatol Rep* **2011**, *13*, 513-520, doi:10.1007/s11926-011-0206-6.
36. Arendt-Nielsen, L.; Nie, H.; Laursen, M.B.; Laursen, B.S.; Madeleine, P.; Simonsen, O.H.; Graven-Nielsen, T. Sensitization in patients with painful knee osteoarthritis. *Pain* **2010**, *149*, 573-581, doi:10.1016/j.pain.2010.04.003.
37. Graven-Nielsen, T.; Wodehouse, T.; Langford, R.M.; Arendt-Nielsen, L.; Kidd, B.L. Normalization of widespread hyperesthesia and facilitated spatial summation of deep-tissue pain in knee osteoarthritis patients after knee replacement. *Arthritis Rheum* **2012**, *64*, 2907-2916, doi:10.1002/art.34466.
38. Kosek, E.; Ordeberg, G. Lack of pressure pain modulation by heterotopic noxious conditioning stimulation in patients with painful osteoarthritis before, but not following, surgical pain relief. *Pain* **2000**, *88*, 69-78, doi:10.1016/S0304-3959(00)00310-9.
39. Lewis, G.N.; Rice, D.A.; McNair, P.J. Conditioned pain modulation in populations with chronic pain: a systematic review and meta-analysis. *J Pain* **2012**, *13*, 936-944, doi:10.1016/j.jpain.2012.07.005.
40. Grosberg, B.; Rabany, L.; Lin, T.; Harris, D.; Vizel, M.; Ironi, A.; O'Carroll, C.P.; Schim, J. Safety and efficacy of remote electrical neuromodulation for the acute treatment of chronic migraine: an open-label study. *Pain Rep* **2021**, *6*, e966, doi:10.1097/PR9.0000000000000966.
41. Yarnitsky, D.; Granot, M.; Nahman-Averbuch, H.; Khamaisi, M.; Granovsky, Y. Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy. *Pain* **2012**, *153*, 1193-1198, doi:10.1016/j.pain.2012.02.021.

42. Niesters, M.; Proto, P.L.; Aarts, L.; Sarton, E.Y.; Drewes, A.M.; Dahan, A. Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy. *Br J Anaesth* **2014**, *113*, 148-156, doi:10.1093/bja/aeu056.
43. Nahman-Averbuch, H.; Yarnitsky, D.; Granovsky, Y.; Sprecher, E.; Steiner, M.; Tzuk-Shina, T.; Pud, D. Pronociceptive pain modulation in patients with painful chemotherapy-induced polyneuropathy. *J Pain Symptom Manage* **2011**, *42*, 229-238, doi:10.1016/j.jpainsymman.2010.10.268.
44. Gruener, H.; Zeilig, G.; Laufer, Y.; Blumen, N.; Defrin, R. Differential pain modulation properties in central neuropathic pain after spinal cord injury. *Pain* **2016**, *157*, 1415-1424, doi:10.1097/j.pain.0000000000000532.
45. Gil-Ugidos, A.; Vazquez-Millan, A.; Samartin-Veiga, N.; Carrillo-de-la-Pena, M.T. Conditioned pain modulation (CPM) paradigm type affects its sensitivity as a biomarker of fibromyalgia. *Sci Rep* **2024**, *14*, 7798, doi:10.1038/s41598-024-58079-7.
46. Arant, K.R.; Katz, J.N.; Neogi, T. Quantitative sensory testing: identifying pain characteristics in patients with osteoarthritis. *Osteoarthritis Cartilage* **2022**, *30*, 17-31, doi:10.1016/j.joca.2021.09.011.
47. Granovsky, Y.; Shafran Topaz, L.; Laycock, H.; Zubiedat, R.; Crystal, S.; Buxbaum, C.; Bosak, N.; Hadad, R.; Domany, E.; Khamaisi, M.; et al. Conditioned pain modulation is more efficient in patients with painful diabetic polyneuropathy than those with nonpainful diabetic polyneuropathy. *Pain* **2022**, *163*, 827-833, doi:10.1097/j.pain.0000000000002434.
48. Neelapala, Y.V.R.; Bhagat, M.; Frey-Law, L. Conditioned Pain Modulation in Chronic Low Back Pain: A Systematic Review of Literature. *Clin J Pain* **2020**, *36*, 135-141, doi:10.1097/AJP.0000000000000778.
49. Nahman-Averbuch, H.; Callahan, D.; Darken, R.; Haroutounian, S. Harnessing the conditioned pain modulation response in migraine diagnosis, outcome prediction, and treatment-A narrative review. *Headache* **2023**, *63*, 1167-1177, doi:10.1111/head.14601.
50. Williams, A.E.; Miller, M.M.; Bartley, E.J.; McCabe, K.M.; Kerr, K.L.; Rhudy, J.L. Impairment of Inhibition of Trigeminal Nociception via Conditioned Pain Modulation in Persons with Migraine Headaches. *Pain Med* **2019**, *20*, 1600-1610, doi:10.1093/pm/pny305.
51. Guy, N.; Voisin, D.; Mulliez, A.; Clavelou, P.; Dallel, R. Medication overuse reinstates conditioned pain modulation in women with migraine. *Cephalalgia* **2018**, *38*, 1148-1158, doi:10.1177/0333102417727545.
52. Kisler, L.B.; Weissman-Fogel, I.; Coghill, R.C.; Sprecher, E.; Yarnitsky, D.; Granovsky, Y. Individualization of Migraine Prevention: A Randomized Controlled Trial of Psychophysical-based Prediction of Duloxetine Efficacy. *Clin J Pain* **2019**, *35*, 753-765, doi:10.1097/AJP.0000000000000739.
53. Granovsky, Y.; Nahman-Averbuch, H.; Khamaisi, M.; Granot, M. Efficient conditioned pain modulation despite pain persistence in painful diabetic neuropathy. *Pain Rep* **2017**, *2*, e592, doi:10.1097/PR9.0000000000000592.
54. Yarnitsky, D.; Bouhassira, D.; Drewes, A.M.; Fillingim, R.B.; Granot, M.; Hansson, P.; Landau, R.; Marchand, S.; Matre, D.; Nilsen, K.B.; et al. Recommendations on practice of conditioned pain modulation (CPM) testing. *Eur J Pain* **2015**, *19*, 805-806, doi:10.1002/ejp.605.
55. Lockwood, S.M.; Bannister, K.; Dickenson, A.H. An investigation into the noradrenergic and serotonergic contributions of diffuse noxious inhibitory controls in a monoiodoacetate model of osteoarthritis. *J Neurophysiol* **2019**, *121*, 96-104, doi:10.1152/jn.00613.2018.
56. Pereira-Silva, R.; Costa-Pereira, J.T.; Alonso, R.; Serrao, P.; Martins, I.; Neto, F.L. Attenuation of the Diffuse Noxious Inhibitory Controls in Chronic Joint Inflammatory Pain Is Accompanied by Anxiodepressive-Like Behaviors and Impairment of the Descending Noradrenergic Modulation. *Int J Mol Sci* **2020**, *21*, doi:10.3390/ijms21082973.
57. Pereira-Silva, R.; Serrao, P.; Lourenca Neto, F.; Martins, I. Diffuse noxious inhibitory controls in chronic joint inflammatory Pain: Study of the descending serotonergic modulation mediated through 5HT3 receptors. *Neurobiol Pain* **2023**, *13*, 100123, doi:10.1016/j.ynpai.2023.100123.
58. Pereira-Silva, R.; Teixeira-Pinto, A.; Neto, F.L.; Martins, I. micro-opioid receptor activation at the dorsal reticular nucleus shifts diffuse noxious inhibitory controls to hyperalgesia in chronic joint pain in male rats. *Anesthesiology* **2024**, doi:10.1097/ALN.0000000000004956.
59. Danziger, N.; Weil-Fugazza, J.; Le Bars, D.; Bouhassira, D. Alteration of descending modulation of nociception during the course of monoarthritis in the rat. *J Neurosci* **1999**, *19*, 2394-2400, doi:10.1523/JNEUROSCI.19-06-02394.1999.
60. Bannister, K.; Lockwood, S.; Goncalves, L.; Patel, R.; Dickenson, A.H. An investigation into the inhibitory function of serotonin in diffuse noxious inhibitory controls in the neuropathic rat. *Eur J Pain* **2017**, *21*, 750-760, doi:10.1002/ejp.979.
61. Bannister, K.; Patel, R.; Goncalves, L.; Townson, L.; Dickenson, A.H. Diffuse noxious inhibitory controls and nerve injury: restoring an imbalance between descending monoamine inhibitions and facilitations. *Pain* **2015**, *156*, 1803-1811, doi:10.1097/j.pain.0000000000000240.
62. Navratilova, E.; Nation, K.; Remeniuk, B.; Neugebauer, V.; Bannister, K.; Dickenson, A.H.; Porreca, F. Selective modulation of tonic aversive qualities of neuropathic pain by morphine in the central nucleus of

- the amygdala requires endogenous opioid signaling in the anterior cingulate cortex. *Pain* **2020**, *161*, 609-618, doi:10.1097/j.pain.0000000000001748.
63. Patel, R.; Dickenson, A.H. A study of cortical and brainstem mechanisms of diffuse noxious inhibitory controls in anaesthetised normal and neuropathic rats. *Eur J Neurosci* **2020**, *51*, 952-962, doi:10.1111/ejn.14576.
 64. Phelps, C.E.; Navratilova, E.; Dickenson, A.H.; Porreca, F.; Bannister, K. Kappa opioid signaling in the right central amygdala causes hind paw specific loss of diffuse noxious inhibitory controls in experimental neuropathic pain. *Pain* **2019**, *160*, 1614-1621, doi:10.1097/j.pain.0000000000001553.
 65. Yoneda, S.; Kasai, E.; Matsuo, M.; Tamano, R.; Sakurai, Y.; Asaki, T.; Fujita, M. Duloxetine ameliorates the impairment of diffuse noxious inhibitory control in rat models of peripheral neuropathic pain and knee osteoarthritis pain. *Neurosci Lett* **2020**, *729*, 134990, doi:10.1016/j.neulet.2020.134990.
 66. Irvine, K.A.; Peters, C.M.; Vazey, E.M.; Ferguson, A.R.; Clark, J.D. Activation of the Locus Coeruleus Mediated by Designer Receptor Exclusively Activated by Designer Drug Restores Descending Nociceptive Inhibition after Traumatic Brain Injury in Rats. *J Neurotrauma* **2022**, *39*, 964-978, doi:10.1089/neu.2021.0485.
 67. Irvine, K.A.; Sahbaie, P.; Ferguson, A.R.; Clark, J.D. Loss of diffuse noxious inhibitory control after traumatic brain injury in rats: A chronic issue. *Exp Neurol* **2020**, *333*, 113428, doi:10.1016/j.expneurol.2020.113428.
 68. Sahbaie, P.; Irvine, K.A.; Shi, X.Y.; Clark, J.D. Monoamine control of descending pain modulation after mild traumatic brain injury. *Sci Rep* **2022**, *12*, 16359, doi:10.1038/s41598-022-20292-7.
 69. Melzack, R. Pain and the neuromatrix in the brain. *J Dent Educ* **2001**, *65*, 1378-1382.
 70. Millan, M.J. Descending control of pain. *Prog Neurobiol* **2002**, *66*, 355-474, doi:10.1016/s0301-0082(02)00009-6.
 71. Bagley, E.E.; Ingram, S.L. Endogenous opioid peptides in the descending pain modulatory circuit. *Neuropharmacology* **2020**, *173*, 108131.
 72. Costa, A.R.; Tavares, I.; Martins, I. How do opioids control pain circuits in the brainstem during opioid-induced disorders and in chronic pain? Implications for the treatment of chronic pain. *Pain* **2024**, *165*, 324-336, doi:10.1097/j.pain.0000000000003026.
 73. Martins, I.; Carvalho, P.; de Vries, M.G.; Teixeira-Pinto, A.; Wilson, S.P.; Westerink, B.H.; Tavares, I. Increased noradrenergic neurotransmission to a pain facilitatory area of the brain is implicated in facilitation of chronic pain. *Anesthesiology* **2015**, *123*, 642-653, doi:10.1097/ALN.0000000000000749.
 74. Martins, I.; Costa-Araujo, S.; Fadel, J.; Wilson, S.P.; Lima, D.; Tavares, I. Reversal of neuropathic pain by HSV-1-mediated decrease of noradrenaline in a pain facilitatory area of the brain. *Pain* **2010**, *151*, 137-145, doi:10.1016/j.pain.2010.06.027.
 75. Martins, I.; de Vries, M.G.; Teixeira-Pinto, A.; Fadel, J.; Wilson, S.P.; Westerink, B.H.; Tavares, I. Noradrenaline increases pain facilitation from the brain during inflammatory pain. *Neuropharmacology* **2013**, *71*, 299-307, doi:10.1016/j.neuropharm.2013.04.007.
 76. Camarena-Delgado, C.; Llorca-Torralba, M.; Suarez-Pereira, I.; Bravo, L.; Lopez-Martin, C.; Garcia-Partida, J.A.; Mico, J.A.; Berrocso, E. Nerve injury induces transient locus coeruleus activation over time: role of the locus coeruleus-dorsal reticular nucleus pathway. *Pain* **2022**, *163*, 943-954, doi:10.1097/j.pain.0000000000002457.
 77. Hirschberg, S.; Li, Y.; Randall, A.; Kremer, E.J.; Pickering, A.E. Functional dichotomy in spinal- vs prefrontal-projecting locus coeruleus modules splits descending noradrenergic analgesia from ascending aversion and anxiety in rats. *Elife* **2017**, *6*, doi:10.7554/eLife.29808.
 78. Martins, I.; Tavares, I. Reticular Formation and Pain: The Past and the Future. *Front Neuroanat* **2017**, *11*, 51, doi:10.3389/fnana.2017.00051.
 79. Lima, D.; Almeida, A. The medullary dorsal reticular nucleus as a pronociceptive centre of the pain control system. *Prog Neurobiol* **2002**, *66*, 81-108, doi:10.1016/s0301-0082(01)00025-9.
 80. Suarez-Pereira, I.; Llorca-Torralba, M.; Bravo, L.; Camarena-Delgado, C.; Soriano-Mas, C.; Berrocso, E. The Role of the Locus Coeruleus in Pain and Associated Stress-Related Disorders. *Biol Psychiatry* **2022**, *91*, 786-797, doi:10.1016/j.biopsych.2021.11.023.
 81. Martins, I.; Pinto, M.; Wilson, S.P.; Lima, D.; Tavares, I. Dynamic of migration of HSV-1 from a medullary pronociceptive centre: antinociception by overexpression of the preproenkephalin transgene. *Eur J Neurosci* **2008**, *28*, 2075-2083, doi:10.1111/j.1460-9568.2008.06492.x.
 82. Pinto, M.; Castro, A.R.; Tshudy, F.; Wilson, S.P.; Lima, D.; Tavares, I. Opioids modulate pain facilitation from the dorsal reticular nucleus. *Mol Cell Neurosci* **2008**, *39*, 508-518, doi:10.1016/j.mcn.2008.07.008.
 83. Pinto, M.; Sousa, M.; Lima, D.; Tavares, I. Participation of mu-opioid, GABA(B), and NK1 receptors of major pain control medullary areas in pathways targeting the rat spinal cord: implications for descending modulation of nociceptive transmission. *J Comp Neurol* **2008**, *510*, 175-187, doi:10.1002/cne.21793.
 84. Costa, A.R.; Carvalho, P.; Flik, G.; Wilson, S.P.; Reguenga, C.; Martins, I.; Tavares, I. Neuropathic Pain Induced Alterations in the Opioidergic Modulation of a Descending Pain Facilitatory Area of the Brain. *Front Cell Neurosci* **2019**, *13*, 287, doi:10.3389/fncel.2019.00287.

85. Costa, A.R.; Sousa, M.; Wilson, S.P.; Reguenga, C.; Teixeira-Pinto, A.; Tavares, I.; Martins, I. Shift of micro-opioid Receptor Signaling in the Dorsal Reticular Nucleus Is Implicated in Morphine-induced Hyperalgesia in Male Rats. *Anesthesiology* **2020**, *133*, 628-644, doi:10.1097/ALN.0000000000003412.
86. Oliva, V.; Hartley-Davies, R.; Moran, R.; Pickering, A.E.; Brooks, J.C. Simultaneous brain, brainstem, and spinal cord pharmacological-fMRI reveals involvement of an endogenous opioid network in attentional analgesia. *Elife* **2022**, *11*, doi:10.7554/eLife.71877.
87. Tracey, I. Neuroimaging mechanisms in pain: from discovery to translation. *Pain* **2017**, *158 Suppl 1*, S115-S122, doi:10.1097/j.pain.0000000000000863.
88. Tavares, I.; Costa-Pereira, J.T.; Martins, I. Monoaminergic and Opioidergic Modulation of Brainstem Circuits: New Insights Into the Clinical Challenges of Pain Treatment? *Front Pain Res (Lausanne)* **2021**, *2*, 696515, doi:10.3389/fpain.2021.696515.
89. De Preter, C.C.; Heinricher, M.M. The 'in's and out's' of descending pain modulation from the rostral ventromedial medulla. *Trends Neurosci* **2024**, *47*, 447-460, doi:10.1016/j.tins.2024.04.006.
90. Ossipov, M.H.; Morimura, K.; Porreca, F. Descending pain modulation and chronification of pain. *Curr Opin Support Palliat Care* **2014**, *8*, 143-151, doi:10.1097/SPC.0000000000000055.
91. Dogrul, B.N.; Machado Kopruszinski, C.; Dolatyari Eslami, M.; Watanabe, M.; Luo, S.; Moreira de Souza, L.H.; Vizin, R.L.; Yue, X.; Palmiter, R.D.; Navratilova, E.; et al. Descending facilitation from rostral ventromedial medulla mu opioid receptor-expressing neurons is necessary for maintenance of sensory and affective dimensions of chronic neuropathic pain. *Pain* **2024**, doi:10.1097/j.pain.0000000000003360.
92. Francois, A.; Low, S.A.; Sypek, E.I.; Christensen, A.J.; Sotoudeh, C.; Beier, K.T.; Ramakrishnan, C.; Ritola, K.D.; Sharif-Naeini, R.; Deisseroth, K.; et al. A Brainstem-Spinal Cord Inhibitory Circuit for Mechanical Pain Modulation by GABA and Enkephalins. *Neuron* **2017**, *93*, 822-839 e826, doi:10.1016/j.neuron.2017.01.008.
93. Zhang, Y.; Zhao, S.; Rodriguez, E.; Takatoh, J.; Han, B.-X.; Zhou, X.; Wang, F. Identifying local and descending inputs for primary sensory neurons. *The Journal of clinical investigation* **2015**, *125*, 3782-3794.
94. Fatt, M.P.; Zhang, M.D.; Kupari, J.; Altinkok, M.; Yang, Y.; Hu, Y.; Svenningsson, P.; Ernfors, P. Morphine-responsive neurons that regulate mechanical antinociception. *Science* **2024**, *385*, eado6593, doi:10.1126/science.ado6593.
95. Pertovaara, A. The noradrenergic pain regulation system: a potential target for pain therapy. *Eur J Pharmacol* **2013**, *716*, 2-7, doi:10.1016/j.ejphar.2013.01.067.
96. Pan, Y.Z.; Li, D.P.; Chen, S.R.; Pan, H.L. Activation of mu-opioid receptors excites a population of locus coeruleus-spinal neurons through presynaptic disinhibition. *Brain Res* **2004**, *997*, 67-78, doi:10.1016/j.brainres.2003.10.050.
97. Howarth, P.W.; Thornton, S.R.; O'Brien, V.; Smith, W.D.; Nikiforova, N.; Teschemacher, A.G.; Pickering, A.E. Retrograde viral vector-mediated inhibition of pontospinal noradrenergic neurons causes hyperalgesia in rats. *J Neurosci* **2009**, *29*, 12855-12864, doi:10.1523/JNEUROSCI.1699-09.2009.
98. Kim, J.H.; Gangadharan, G.; Byun, J.; Choi, E.J.; Lee, C.J.; Shin, H.S. Yin-and-yang bifurcation of opioidergic circuits for descending analgesia at the midbrain of the mouse. *Proc Natl Acad Sci U S A* **2018**, *115*, 11078-11083, doi:10.1073/pnas.1806082115.
99. Al-Hasani, R.; Bruchas, M.R. Molecular mechanisms of opioid receptor-dependent signaling and behavior. *Anesthesiology* **2011**, *115*, 1363-1381, doi:10.1097/ALN.0b013e318238bba6.
100. Chakrabarti, S.; Liu, N.J.; Gintzler, A.R. Relevance of Mu-Opioid Receptor Splice Variants and Plasticity of Their Signaling Sequelae to Opioid Analgesic Tolerance. *Cell Mol Neurobiol* **2021**, *41*, 855-862, doi:10.1007/s10571-020-00934-y.
101. Marrone, G.F.; Le Rouzic, V.; Varadi, A.; Xu, J.; Rajadhyaksha, A.M.; Majumdar, S.; Pan, Y.X.; Pasternak, G.W. Genetic dissociation of morphine analgesia from hyperalgesia in mice. *Psychopharmacology (Berl)* **2017**, *234*, 1891-1900, doi:10.1007/s00213-017-4600-2.
102. Wang, H.Y.; Friedman, E.; Olmstead, M.C.; Burns, L.H. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling. *Neuroscience* **2005**, *135*, 247-261, doi:10.1016/j.neuroscience.2005.06.003.
103. Pertovaara, A. Noradrenergic pain modulation. *Prog Neurobiol* **2006**, *80*, 53-83, doi:10.1016/j.pneurobio.2006.08.001.
104. Kucharczyk, M.W.; Di Domenico, F.; Bannister, K. Distinct brainstem to spinal cord noradrenergic pathways inversely regulate spinal neuronal activity. *Brain* **2022**, *145*, 2293-2300, doi:10.1093/brain/awac085.
105. Cortes-Altamirano, J.L.; Olmos-Hernandez, A.; Jaime, H.B.; Carrillo-Mora, P.; Bandala, C.; Reyes-Long, S.; Alfaro-Rodriguez, A. Review: 5-HT1, 5-HT2, 5-HT3 and 5-HT7 Receptors and their Role in the Modulation of Pain Response in the Central Nervous System. *Curr Neuropharmacol* **2018**, *16*, 210-221, doi:10.2174/1570159X15666170911121027.

106. Tao, Z.Y.; Wang, P.X.; Wei, S.Q.; Traub, R.J.; Li, J.F.; Cao, D.Y. The Role of Descending Pain Modulation in Chronic Primary Pain: Potential Application of Drugs Targeting Serotonergic System. *Neural Plast* **2019**, 2019, 1389296, doi:10.1155/2019/1389296.
107. Adell, A.; Garcia-Marquez, C.; Armario, A.; Gelpi, E. Chronic stress increases serotonin and noradrenaline in rat brain and sensitizes their responses to a further acute stress. *J Neurochem* **1988**, 50, 1678-1681, doi:10.1111/j.1471-4159.1988.tb02462.x.
108. Villanueva, L.; Cadden, S.W.; Le Bars, D. Evidence that diffuse noxious inhibitory controls (DNIC) are mediated by a final post-synaptic inhibitory mechanism. *Brain Res* **1984**, 298, 67-74, doi:10.1016/0006-8993(84)91147-8.
109. Okada, K.; Oshima, M.; Kawakita, K. Examination of the afferent fiber responsible for the suppression of jaw-opening reflex in heat, cold, and manual acupuncture stimulation in rats. *Brain Res* **1996**, 740, 201-207, doi:10.1016/s0006-8993(96)00863-3.
110. Bouhassira, D.; Villanueva, L.; Bing, Z.; le Bars, D. Involvement of the subnucleus reticularis dorsalis in diffuse noxious inhibitory controls in the rat. *Brain Res* **1992**, 595, 353-357, doi:10.1016/0006-8993(92)91071-1.
111. Roby-Brami, A.; Bussel, B.; Willer, J.C.; Le Bars, D. An electrophysiological investigation into the pain-relieving effects of heterotopic nociceptive stimuli. Probable involvement of a supraspinal loop. *Brain* **1987**, 110 (Pt 6), 1497-1508, doi:10.1093/brain/110.6.1497.
112. van Wijk, G.; Veldhuijzen, D.S. Perspective on diffuse noxious inhibitory controls as a model of endogenous pain modulation in clinical pain syndromes. *J Pain* **2010**, 11, 408-419, doi:10.1016/j.jpain.2009.10.009.
113. Bester, H.; Chapman, V.; Besson, J.M.; Bernard, J.F. Physiological properties of the lamina I spinoparabrachial neurons in the rat. *J Neurophysiol* **2000**, 83, 2239-2259, doi:10.1152/jn.2000.83.4.2239.
114. Lapirot, O.; Chebbi, R.; Monconduit, L.; Artola, A.; Dallel, R.; Luccarini, P. NK1 receptor-expressing spinoparabrachial neurons trigger diffuse noxious inhibitory controls through lateral parabrachial activation in the male rat. *Pain* **2009**, 142, 245-254, doi:10.1016/j.pain.2009.01.015.
115. Suzuki, R.; Morcuende, S.; Webber, M.; Hunt, S.P.; Dickenson, A.H. Superficial NK1-expressing neurons control spinal excitability through activation of descending pathways. *Nat Neurosci* **2002**, 5, 1319-1326, doi:10.1038/nn966.
116. Castro, A.R.; Pinto, M.; Lima, D.; Tavares, I. Nociceptive spinal neurons expressing NK1 and GABAB receptors are located in lamina I. *Brain Res* **2004**, 1003, 77-85, doi:10.1016/j.brainres.2003.12.027.
117. Pauli, J.L.; Chen, J.Y.; Basiri, M.L.; Park, S.; Carter, M.E.; Sanz, E.; McKnight, G.S.; Stuber, G.D.; Palmiter, R.D. Molecular and anatomical characterization of parabrachial neurons and their axonal projections. *Elife* **2022**, 11, doi:10.7554/eLife.81868.
118. Conte, D.; Legg, E.D.; McCourt, A.C.; Silajdzic, E.; Nagy, G.G.; Maxwell, D.J. Transmitter content, origins and connections of axons in the spinal cord that possess the serotonin (5-hydroxytryptamine) 3 receptor. *Neuroscience* **2005**, 134, 165-173, doi:10.1016/j.neuroscience.2005.02.013.
119. Le Bars, D.; Villanueva, L.; Bouhassira, D.; Willer, J.C. Diffuse noxious inhibitory controls (DNIC) in animals and in man. *Patol Fiziol Eksp Ter* **1992**, 55-65.
120. Villanueva, L.; Le Bars, D. The activation of bulbo-spinal controls by peripheral nociceptive inputs: diffuse noxious inhibitory controls. *Biol Res* **1995**, 28, 113-125.
121. Villanueva, L.; Peschanski, M.; Calvino, B.; Le Bars, D. Ascending pathways in the spinal cord involved in triggering of diffuse noxious inhibitory controls in the rat. *J Neurophysiol* **1986**, 55, 34-55, doi:10.1152/jn.1986.55.1.34.
122. Bouhassira, D.; Bing, Z.; Le Bars, D. Studies of the brain structures involved in diffuse noxious inhibitory controls: the mesencephalon. *J Neurophysiol* **1990**, 64, 1712-1723, doi:10.1152/jn.1990.64.6.1712.
123. Bouhassira, D.; Chitour, D.; Villanueva, L.; Le Bars, D. Morphine and diffuse noxious inhibitory controls in the rat: effects of lesions of the rostral ventromedial medulla. *Eur J Pharmacol* **1993**, 232, 207-215, doi:10.1016/0014-2999(93)90775-d.
124. Chitour, D.; Dickenson, A.H.; Le Bars, D. Pharmacological evidence for the involvement of serotonergic mechanisms in diffuse noxious inhibitory controls (DNIC). *Brain Res* **1982**, 236, 329-337, doi:10.1016/0006-8993(82)90718-1.
125. Dickenson, A.H.; Le Bars, D. Morphine microinjections into periaqueductal grey matter of the rat: effects on dorsal horn neuronal responses to C-fibre activity and diffuse noxious inhibitory controls. *Life Sci* **1983**, 33 Suppl 1, 549-552, doi:10.1016/0024-3205(83)90562-3.
126. Dickenson, A.H.; Rivot, J.P.; Chaouch, A.; Besson, J.M.; Le Bars, D. Diffuse noxious inhibitory controls (DNIC) in the rat with or without pCPA pretreatment. *Brain Res* **1981**, 216, 313-321, doi:10.1016/0006-8993(81)90133-5.
127. Chebbi, R.; Boyer, N.; Monconduit, L.; Artola, A.; Luccarini, P.; Dallel, R. The nucleus raphe magnus OFF-cells are involved in diffuse noxious inhibitory controls. *Exp Neurol* **2014**, 256, 39-45, doi:10.1016/j.expneurol.2014.03.006.

128. Kucharczyk, M.W.; Di Domenico, F.; Bannister, K. A critical brainstem relay for mediation of diffuse noxious inhibitory controls. *Brain* **2023**, *146*, 2259-2267, doi:10.1093/brain/awad002.
129. Le Bars, D. The whole body receptive field of dorsal horn multireceptive neurones. *Brain Res Brain Res Rev* **2002**, *40*, 29-44, doi:10.1016/s0165-0173(02)00186-8.
130. Villanueva, L.; Bouhassira, D.; Le Bars, D. The medullary subnucleus reticularis dorsalis (SRD) as a key link in both the transmission and modulation of pain signals. *Pain* **1996**, *67*, 231-240, doi:10.1016/0304-3959(96)03121-1.
131. Damien, J.; Colloca, L.; Bellei-Rodriguez, C.E.; Marchand, S. Pain Modulation: From Conditioned Pain Modulation to Placebo and Nocebo Effects in Experimental and Clinical Pain. *Int Rev Neurobiol* **2018**, *139*, 255-296, doi:10.1016/bs.irn.2018.07.024.
132. Moont, R.; Crispel, Y.; Lev, R.; Pud, D.; Yarnitsky, D. Temporal changes in cortical activation during conditioned pain modulation (CPM), a LORETA study. *Pain* **2011**, *152*, 1469-1477, doi:10.1016/j.pain.2011.01.036.
133. Sirucek, L.; Ganley, R.P.; Zeilhofer, H.U.; Schweinhardt, P. Diffuse noxious inhibitory controls and conditioned pain modulation: a shared neurobiology within the descending pain inhibitory system? *Pain* **2023**, *164*, 463-468, doi:10.1097/j.pain.0000000000002719.
134. Nemoto, W.; Kozak, D.; Sotocinal, S.G.; Tansley, S.; Bannister, K.; Mogil, J.S. Monoaminergic mediation of hyperalgesic and analgesic descending control of nociception in mice. *Pain* **2023**, *164*, 1096-1105, doi:10.1097/j.pain.0000000000002806.
135. Costa-Pereira, J.T.; Serrao, P.; Martins, I.; Tavares, I. Serotonergic pain modulation from the rostral ventromedial medulla (RVM) in chemotherapy-induced neuropathy: The role of spinal 5-HT₃ receptors. *Eur J Neurosci* **2020**, *51*, 1756-1769, doi:10.1111/ejn.14614.
136. Kraus, E.; Besson, J.M.; Le Bars, D. Behavioral model for diffuse noxious inhibitory controls (DNIC): potentiation by 5-hydroxytryptophan. *Brain Res* **1982**, *231*, 461-465, doi:10.1016/0006-8993(82)90384-5.
137. Itomi, Y.; Tsukimi, Y.; Kawamura, T. Impaired diffuse noxious inhibitory controls in specific alternation of rhythm in temperature-stressed rats. *Eur J Pharmacol* **2016**, *784*, 61-68, doi:10.1016/j.ejphar.2016.05.011.
138. Nation, K.M.; Dodick, D.W.; Navratilova, E.; Porreca, F. Sustained exposure to acute migraine medications combined with repeated noxious stimulation dysregulates descending pain modulatory circuits: Relevance to medication overuse headache. *Cephalalgia* **2019**, *39*, 617-625, doi:10.1177/0333102418804157.
139. Brenchat, A.; Nadal, X.; Romero, L.; Ovalle, S.; Muro, A.; Sanchez-Arroyos, R.; Portillo-Salido, E.; Pujol, M.; Montero, A.; Codony, X.; et al. Pharmacological activation of 5-HT₇ receptors reduces nerve injury-induced mechanical and thermal hypersensitivity. *Pain* **2010**, *149*, 483-494, doi:10.1016/j.pain.2010.03.007.
140. Alhaider, A.A.; Lei, S.Z.; Wilcox, G.L. Spinal 5-HT₃ receptor-mediated antinociception: possible release of GABA. *J Neurosci* **1991**, *11*, 1881-1888, doi:10.1523/JNEUROSCI.11-07-01881.1991.
141. Ali, Z.; Wu, G.; Kozlov, A.; Barasi, S. The role of 5HT₃ in nociceptive processing in the rat spinal cord: results from behavioural and electrophysiological studies. *Neurosci Lett* **1996**, *208*, 203-207, doi:10.1016/0304-3940(95)12600-7.
142. Green, M.G.; Scarth, J.; Dickenson, A. An excitatory role for 5-HT in spinal inflammatory nociceptive transmission; state-dependent actions via dorsal horn 5-HT₃ receptors in the anaesthetized rat. *Pain* **2000**, *89*, 81-88, doi:10.1016/S0304-3959(00)00346-8.
143. Bétry, C.; Etiévant, A.; Oosterhof, C.; Ebert, B.; Sanchez, C.; Haddjeri, N. Role of 5-HT₃ Receptors in the Antidepressant Response. *Pharmaceuticals* **2011**, *4*, 603-629.
144. Okada, M.; Okubo, R.; Fukuyama, K. Vortioxetine Subchronically Activates Serotonergic Transmission via Desensitization of Serotonin 5-HT_{1A} Receptor with 5-HT₃ Receptor Inhibition in Rats. *Int J Mol Sci* **2019**, *20*, doi:10.3390/ijms20246235.
145. Wen, Y.R.; Wang, C.C.; Yeh, G.C.; Hsu, S.F.; Huang, Y.J.; Li, Y.L.; Sun, W.Z. DNIC-mediated analgesia produced by a supramaximal electrical or a high-dose formalin conditioning stimulus: roles of opioid and alpha₂-adrenergic receptors. *J Biomed Sci* **2010**, *17*, 19, doi:10.1186/1423-0127-17-19.
146. De Felice, M.; Ossipov, M.H. Cortical and subcortical modulation of pain. *Pain Manag* **2016**, *6*, 111-120, doi:10.2217/pmt.15.63.
147. Ossipov, M.H.; Dussor, G.O.; Porreca, F. Central modulation of pain. *J Clin Invest* **2010**, *120*, 3779-3787, doi:10.1172/JCI43766.
148. Baba, H.; Goldstein, P.A.; Okamoto, M.; Kohno, T.; Ataka, T.; Yoshimura, M.; Shimoji, K. Norepinephrine facilitates inhibitory transmission in substantia gelatinosa of adult rat spinal cord (part 2): effects on somatodendritic sites of GABAergic neurons. *Anesthesiology* **2000**, *92*, 485-492, doi:10.1097/00000542-200002000-00031.
149. Baba, H.; Shimoji, K.; Yoshimura, M. Norepinephrine facilitates inhibitory transmission in substantia gelatinosa of adult rat spinal cord (part 1): effects on axon terminals of GABAergic and glycinergic neurons. *Anesthesiology* **2000**, *92*, 473-484, doi:10.1097/00000542-200002000-00030.
150. Gassner, M.; Ruscheweyh, R.; Sandkuhler, J. Direct excitation of spinal GABAergic interneurons by noradrenaline. *Pain* **2009**, *145*, 204-210, doi:10.1016/j.pain.2009.06.021.

151. Budai, D.; Harasawa, I.; Fields, H.L. Midbrain periaqueductal gray (PAG) inhibits nociceptive inputs to sacral dorsal horn nociceptive neurons through alpha2-adrenergic receptors. *J Neurophysiol* **1998**, *80*, 2244-2254, doi:10.1152/jn.1998.80.5.2244.
152. Le Bars, D.; Willer, J.C.; De Broucker, T. Morphine blocks descending pain inhibitory controls in humans. *Pain* **1992**, *48*, 13-20, doi:10.1016/0304-3959(92)90126-V.
153. Willer, J.C.; Le Bars, D.; De Broucker, T. Diffuse noxious inhibitory controls in man: involvement of an opioidergic link. *Eur J Pharmacol* **1990**, *182*, 347-355, doi:10.1016/0014-2999(90)90293-f.
154. Bouhassira, D.; Villanueva, L.; Le Bars, D. Intracerebroventricular morphine decreases descending inhibitions acting on lumbar dorsal horn neuronal activities related to pain in the rat. *J Pharmacol Exp Ther* **1988**, *247*, 332-342.
155. Duale, C.; Molat, J.L.; Dallel, R. Morphine microinjected into the nucleus raphe magnus does not block the activity of spinal trigeminal nucleus oralis convergent neurons in the rat. *Brain Res* **1998**, *803*, 208-211, doi:10.1016/S0006-8993(98)00659-3.
156. Okada-Ogawa, A.; Porreca, F.; Meng, I.D. Sustained morphine-induced sensitization and loss of diffuse noxious inhibitory controls in dura-sensitive medullary dorsal horn neurons. *J Neurosci* **2009**, *29*, 15828-15835, doi:10.1523/JNEUROSCI.3623-09.2009.
157. Navratilova, E.; Ji, G.; Phelps, C.; Qu, C.; Hein, M.; Yakhnitsa, V.; Neugebauer, V.; Porreca, F. Kappa opioid signaling in the central nucleus of the amygdala promotes disinhibition and aversiveness of chronic neuropathic pain. *Pain* **2019**, *160*, 824-832, doi:10.1097/j.pain.0000000000001458.
158. Bee, L.A.; Bannister, K.; Rahman, W.; Dickenson, A.H. Mu-opioid and noradrenergic alpha(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats. *Pain* **2011**, *152*, 131-139, doi:10.1016/j.pain.2010.10.004.
159. Corder, G.; Castro, D.C.; Bruchas, M.R.; Scherrer, G. Endogenous and exogenous opioids in pain. *Annual review of neuroscience* **2018**, *41*, 453-473.
160. Sun, J.; Chen, S.R.; Pan, H.L. mu-Opioid receptors in primary sensory neurons are involved in supraspinal opioid analgesia. *Brain Res* **2020**, *1729*, 146623, doi:10.1016/j.brainres.2019.146623.
161. Wang, D.; Zeng, J.; Li, Q.; Huang, J.; Couture, R.; Hong, Y. Contribution of adrenomedullin to the switch of G protein-coupled mu-opioid receptors from Gi to Gs in the spinal dorsal horn following chronic morphine exposure in rats. *Br J Pharmacol* **2016**, *173*, 1196-1207, doi:10.1111/bph.13419.
162. Dugast, C.; Almeida, A.; Lima, D. The medullary dorsal reticular nucleus enhances the responsiveness of spinal nociceptive neurons to peripheral stimulation in the rat. *Eur J Neurosci* **2003**, *18*, 580-588, doi:10.1046/j.1460-9568.2003.02782.x.
163. Bannister, K.; Kucharczyk, M.W.; Graven-Nielsen, T.; Porreca, F. Introducing descending control of nociception: a measure of diffuse noxious inhibitory controls in conscious animals. *Pain* **2021**, *162*, 1957-1959, doi:10.1097/j.pain.0000000000002203.
164. Firouzian, S.; Osborne, N.R.; Cheng, J.C.; Kim, J.A.; Bosma, R.L.; Hemington, K.S.; Rogachov, A.; Davis, K.D. Individual variability and sex differences in conditioned pain modulation and the impact of resilience, and conditioning stimulus pain unpleasantness and salience. *Pain* **2020**, *161*, 1847-1860, doi:10.1097/j.pain.0000000000001863.
165. Kennedy, D.L.; Kemp, H.I.; Wu, C.; Ridout, D.A.; Rice, A.S.C. Determining Real Change in Conditioned Pain Modulation: A Repeated Measures Study in Healthy Volunteers. *J Pain* **2020**, *21*, 708-721, doi:10.1016/j.jpain.2019.09.010.
166. Tansley, S.N.; Macintyre, L.C.; Diamond, L.; Sotocinal, S.G.; George, N.; Meluban, L.; Austin, J.S.; Coderre, T.J.; Martin, L.J.; Mogil, J.S. Conditioned pain modulation in rodents can feature hyperalgesia or hypoalgesia depending on test stimulus intensity. *Pain* **2019**, *160*, 784-792, doi:10.1097/j.pain.0000000000001454.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.